



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/00, C07K 14/47, G01N 33/53		A2	(11) International Publication Number: WO 00/52151 (43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number: PCT/US00/05621 (22) International Filing Date: 3 March 2000 (03.03.00)		Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US).	
(30) Priority Data: 60/123,117 5 March 1999 (05.03.99) US		(74) Agents: HAMLET-COX, Diana et al.; Incyte Pharmaceuticals, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/123,117 (CIP) Filed on 5 March 1999 (05.03.99)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (<i>for all designated States except US</i>): INCYTE PHARMACEUTICALS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). LU, Dyung, Aina, M. [US/US]; 55 Park			
(54) Title: HUMAN SECRETORY PROTEINS			
(57) Abstract			
<p>The invention provides human secretory proteins (HSECP) and polynucleotides which identify and encode HSECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSECP.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

HUMAN SECRETORY PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human secretory proteins
5 and to the use of these sequences in the diagnosis, treatment, and prevention of cancer, inflammation,
and gastrointestinal, cardiovascular, and neurological disorders.

BACKGROUND OF THE INVENTION

Protein transport and secretion are essential for cellular function. Protein transport is
10 mediated by a signal peptide located at the amino terminus of the protein to be transported or
secreted. The signal peptide is comprised of about ten to twenty hydrophobic amino acids which
target the nascent protein from the ribosome to a particular membrane bound compartment such as the
endoplasmic reticulum (ER). Proteins targeted to the ER may either proceed through the secretory
pathway or remain in any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes.
15 Proteins that transit through the secretory pathway are either secreted into the extracellular space or
retained in the plasma membrane. Secreted proteins are often synthesized as inactive precursors that
are activated by post-translational processing events during transit through the secretory pathway.
Such events include glycosylation, proteolysis, and removal of the signal peptide by a signal
peptidase. Other events that may occur during protein transport include chaperone-dependent
20 unfolding and folding of the nascent protein and interaction of the protein with a receptor or pore
complex. Examples of secreted proteins with amino terminal signal peptides are discussed below and
include receptors, extracellular matrix molecules, cytokines, hormones, growth and differentiation
factors, neuropeptides, vasomediators, ion channels, transporters/pumps, and proteases. (Reviewed in
Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York, NY, pp. 557-
25 560, 582-592.)

G-protein coupled receptors (GPCRs) comprise a superfamily of integral membrane proteins
which transduce extracellular signals. Not all GPCRs contain N-terminal signal peptides. GPCRs
include receptors for biogenic amines such as dopamine, epinephrine, histamine, glutamate
(metabotropic-type), acetylcholine (muscarinic-type); and serotonin; for lipid mediators of
30 inflammation such as prostaglandins, platelet activating factor, and leukotrienes; for peptide
hormones such as calcitonin, C5a anaphylatoxin, follicle stimulating hormone, gonadotropin releasing
hormone, neurokinin, oxytocin, and thrombin; and for sensory signal mediators such as retinal
photopigments and olfactory stimulatory molecules. The structure of these highly conserved
receptors consists of seven hydrophobic transmembrane regions, cysteine disulfide bridges between
35 the second and third extracellular loops, an extracellular N-terminus, and a cytoplasmic C-terminus.

The N-terminus interacts with ligands, the disulfide bridges interact with agonists and antagonists, and the large third intracellular loop interacts with G proteins to activate second messengers such as cyclic AMP, phospholipase C, inositol triphosphate, or ion channels. (Reviewed in Watson, S. and Arkinstall, S. (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego, CA, pp. 2-6; and Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego, CA, pp. 162-176.)

Other types of receptors include cell surface antigens identified on leukocytic cells of the immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)-based "shot gun" techniques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into "clusters of differentiation" based on common immunocytochemical localization patterns in various differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to identify a single cell surface protein and are assigned a "cluster of differentiation" or "CD" designation. Some of the genes encoding proteins identified by CD antigens have been cloned and verified by standard molecular biology techniques. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed in Barclay, A. N. et al. (1995) The Leucocyte Antigen Facts Book, Academic Press, San Diego, CA, pp. 17-20.)

Matrix proteins (MPs) are transmembrane and extracellular proteins which function in formation, growth, remodeling, and maintenance of tissues and as important mediators and regulators of the inflammatory response. The expression and balance of MPs may be perturbed by biochemical changes that result from congenital, epigenetic, or infectious diseases. In addition, MPs affect leukocyte migration, proliferation, differentiation, and activation in the immune response. MPs are frequently characterized by the presence of one or more domains which may include collagen-like domains, EGF-like domains, immunoglobulin-like domains, and fibronectin-like domains. In addition, MPs may be heavily glycosylated and may contain an Arginine-Glycine-Aspartate (RGD) tripeptide motif which may play a role in adhesive interactions. MPs include extracellular proteins such as fibronectin, collagen, galectin, vitronectin and its proteolytic derivative somatomedin B; and cell adhesion receptors such as cell adhesion molecules (CAMs), cadherins, and integrins. (Reviewed in Ayad, S. et al. (1994) The Extracellular Matrix Facts Book, Academic Press, San Diego, CA, pp. 2-16; Ruoslahti, E. (1997) Kidney Int. 51:1413-1417; Sjaastad, M.D. and Nelson, W.J. (1997) BioEssays 19:47-55.)

Cytokines are secreted by hematopoietic cells in response to injury or infection. Interleukins, neurotrophins, growth factors, interferons, and chemokines all define cytokine families that work in

conjunction with cellular receptors to regulate cell proliferation and differentiation. In addition, cytokines effect activities such as leukocyte migration and function, hematopoietic cell proliferation, temperature regulation, acute response to infection, tissue remodeling, and apoptosis.

Chemokines, in particular, are small chemoattractant cytokines involved in inflammation, 5 leukocyte proliferation and migration, angiogenesis and angiostasis, regulation of hematopoiesis, HIV infectivity, and stimulation of cytokine secretion. Chemokines generally contain 70-100 amino acids and are subdivided into four subfamilies based on the presence of conserved cysteine-based motifs. (Callard, R. and Gearing, A. (1994) The Cytokine Facts Book, Academic Press, New York, NY, pp. 181-190, 210-213, 223-227.)

10 Growth and differentiation factors are secreted proteins which function in intercellular communication. Some factors require oligomerization or association with MPs for activity. Complex interactions among these factors and their receptors trigger intracellular signal transduction pathways that stimulate or inhibit cell division, cell differentiation, cell signaling, and cell motility. Most growth and differentiation factors act on cells in their local environment (paracrine signaling). There
15 are three broad classes of growth and differentiation factors. The first class includes the large polypeptide growth factors such as epidermal growth factor, fibroblast growth factor, transforming growth factor, insulin-like growth factor, and platelet-derived growth factor. The second class includes the hematopoietic growth factors such as the colony stimulating factors (CSFs). Hematopoietic growth factors stimulate the proliferation and differentiation of blood cells such as B-
20 lymphocytes, T-lymphocytes, erythrocytes, platelets, eosinophils, basophils, neutrophils, macrophages, and their stem cell precursors. The third class includes small peptide factors such as bombesin, vasopressin, oxytocin, endothelin, transferrin, angiotensin II, vasoactive intestinal peptide, and bradykinin which function as hormones to regulate cellular functions other than proliferation.

Growth and differentiation factors play critical roles in neoplastic transformation of cells in 25 vitro and in tumor progression in vivo. Inappropriate expression of growth factors by tumor cells may contribute to vascularization and metastasis of tumors. During hematopoiesis, growth factor misregulation can result in anemias, leukemias, and lymphomas. Certain growth factors such as interferon are cytotoxic to tumor cells both in vivo and in vitro. Moreover, some growth factors and growth factor receptors are related both structurally and functionally to oncoproteins. In addition,
30 growth factors affect transcriptional regulation of both proto-oncogenes and oncosuppressor genes.
(Reviewed in Pimentel, E. (1994) Handbook of Growth Factors, CRC Press, Ann Arbor, MI, pp. 1-9.)

Proteolytic enzymes or proteases either activate or deactivate proteins by hydrolyzing peptide bonds. Proteases are found in the cytosol, in membrane-bound compartments, and in the extracellular space. The major families are the zinc, serine, cysteine, thiol, and carboxyl proteases.

35 Ion channels, ion pumps, and transport proteins mediate the transport of molecules across

cellular membranes. Transport can occur by a passive, concentration-dependent mechanism or can be linked to an energy source such as ATP hydrolysis. Symporters and antiporters transport ions and small molecules such as amino acids, glucose, and drugs. Symporters transport molecules and ions unidirectionally, and antiporters transport molecules and ions bidirectionally. Transporter 5 superfamilies include facilitative transporters and active ATP-binding cassette transporters which are involved in multiple-drug resistance and the targeting of antigenic peptides to MHC Class I molecules. These transporters bind to a specific ion or other molecule and undergo a conformational change in order to transfer the ion or molecule across the membrane. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York, NY, pp. 523-546.)

10 Ion channels are formed by transmembrane proteins which create a lined passageway across the membrane through which water and ions, such as Na^+ , K^+ , Ca^{2+} , and Cl^- , enter and exit the cell. For example, chloride channels are involved in the regulation of the membrane electric potential as well as absorption and secretion of ions across the membrane. Chloride channels also regulate the internal pH of membrane-bound organelles.

15 Ion pumps are ATPases which actively maintain membrane gradients. Ion pumps are classified as P, V, or F according to their structure and function. All have one or more binding sites for ATP in their cytosolic domains. The P-class ion pumps include Ca^{2+} ATPase and Na^+/K^+ ATPase and function in transporting H^+ , Na^+ , K^+ , and Ca^{2+} ions. P-class pumps consist of two α and two β transmembrane subunits. The V- and F-class ion pumps have similar structures but transport only H^+ .
20 F class H^+ pumps mediate transport across the membranes of mitochondria and chloroplasts, while V-class H^+ pumps regulate acidity inside lysosomes, endosomes, and plant vacuoles.

A family of structurally related intrinsic membrane proteins known as facilitative glucose 25 transporters catalyze the movement of glucose and other selected sugars across the plasma membrane. The proteins in this family contain a highly conserved, large transmembrane domain comprised of 12 α -helices, and several weakly conserved, cytoplasmic and exoplasmic domains. (Pessin, J. E., and Bell, G.I. (1992) *Annu. Rev. Physiol.* 54:911-930.)

Amino acid transport is mediated by Na^+ dependent amino acid transporters. These 30 transporters are involved in gastrointestinal and renal uptake of dietary and cellular amino acids and in neuronal reuptake of neurotransmitters. Transport of cationic amino acids is mediated by the system y⁺ family and the cationic amino acid transporter (CAT) family. Members of the CAT family share a high degree of sequence homology, and each contains 12-14 putative transmembrane domains. (Ito, K. and Groudine, M. (1997) *J. Biol. Chem.* 272:26780-26786.)

Hormones are secreted molecules that travel through the circulation and bind to specific 35 receptors on the surface of, or within, target cells. Although they have diverse biochemical compositions and mechanisms of action, hormones can be grouped into two categories. One category

includes small lipophilic hormones that diffuse through the plasma membrane of target cells, bind to cytosolic or nuclear receptors, and form a complex that alters gene expression. Examples of these molecules include retinoic acid, thyroxine, and the cholesterol-derived steroid hormones such as progesterone, estrogen, testosterone, cortisol, and aldosterone. The second category includes

5 hydrophilic hormones that function by binding to cell surface receptors that transduce signals across the plasma membrane. Examples of such hormones include amino acid derivatives such as catecholamines and peptide hormones such as glucagon, insulin, gastrin, secretin, cholecystokinin, adrenocorticotrophic hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating hormone, and vasopressin. (See, for example, Lodish et al. (1995) Molecular Cell Biology, Scientific

10 American Books Inc., New York, NY, pp. 856-864.)

Neuropeptides and vasomediators (NP/VM) comprise a large family of endogenous signaling molecules. Included in this family are neuropeptides and neuropeptide hormones such as bombesin, neuropeptide Y, neuropeptid Y, neuropeptid N, neuromedin N, melanocortins, opioids, galanin, somatostatin, tachykinins, urotensin II and related peptides involved in smooth muscle stimulation, vasopressin,

15 vasoactive intestinal peptide, and circulatory system-borne signaling molecules such as angiotensin, complement, calcitonin, endothelins, formyl-methionyl peptides, glucagon, cholecystokinin and gastrin. NP/VMs can transduce signals directly, modulate the activity or release of other neurotransmitters and hormones, and act as catalytic enzymes in cascades. The effects of NP/VMs range from extremely brief to long-lasting. (Reviewed in Martin, C. R. et al. (1985) Endocrine

20 Physiology, Oxford University Press, New York, NY, pp. 57-62.)

The discovery of new human secretory proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cancer, inflammation, and gastrointestinal, cardiovascular, and neurological disorders.

25

SUMMARY OF THE INVENTION

The invention features purified polypeptides, human secretory proteins, referred to collectively as "HSECP" and individually as "HSECP-1," "HSECP-2," "HSECP-3," "HSECP-4," "HSECP-5," "HSECP-6," "HSECP-7," "HSECP-8," "HSECP-9," "HSECP-10," "HSECP-11," "HSECP-12," "HSECP-13," "HSECP-14," "HSECP-15," "HSECP-16," "HSECP-17," "HSECP-18," "HSECP-19," "HSECP-20," "HSECP-21" and "HSECP-22." In one aspect, the invention provides an isolated polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or d) an

immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-22.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising
5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. In one
10 alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:23-44.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group
15 consisting of SEQ ID NO:1-22, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

20 The invention also provides a method for producing a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or d) an immunogenic fragment of an amino
25 acid sequence selected from the group consisting of SEQ ID NO:1-22. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

30 Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID
35 NO:1-22.

The invention further provides an isolated polynucleotide comprising a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, c) a polynucleotide sequence complementary to a), or d) a polynucleotide sequence complementary to b). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44, c) a polynucleotide sequence complementary to a), or d) a polynucleotide sequence complementary to b). The method comprises a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 30 contiguous nucleotides. In another alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a pharmaceutical composition comprising an effective amount of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, and a pharmaceutically acceptable excipient. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional HSECp, comprising administering to a patient in need of such treatment the pharmaceutical composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. The method comprises a) exposing a sample comprising the polypeptide to a

compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a pharmaceutical composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional HSECP,
5 comprising administering to a patient in need of such treatment the pharmaceutical composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-22,
10 c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-22. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a pharmaceutical composition comprising an antagonist compound identified by
15 the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional HSECP, comprising administering to a patient in need of such treatment the pharmaceutical composition.

The invention further provides a method for screening a compound for effectiveness in
20 altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:23-44, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

25

BRIEF DESCRIPTION OF THE TABLES

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding HSECP.

Table 2 shows features of each polypeptide sequence, including predicted signal peptides and
30 other motifs, and methods, algorithms, and searchable databases used for analysis of HSECP.

Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

35 Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones

encoding HSECP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze HSECP, along with applicable descriptions, references, and threshold parameters.

5

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which
10 will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so
15 forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now
20 described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

25 "HSECP" refers to the amino acid sequences of substantially purified HSECP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of HSECP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other
30 compound or composition which modulates the activity of HSECP either by directly interacting with HSECP or by acting on components of the biological pathway in which HSECP participates.

An "allelic variant" is an alternative form of the gene encoding HSECP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or
35 many allelic variants of its naturally occurring form. Common mutational changes which give rise to

allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

- “Altered” nucleic acid sequences encoding HSECP include those sequences with deletions, 5 insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as HSECP or a polypeptide with at least one functional characteristic of HSECP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding HSECP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding 10 HSECP. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HSECP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of HSECP is retained. For example, 15 negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.
- 20 The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to an amino acid sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein 25 molecule.

“Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

- The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity 30 of HSECP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of HSECP either by directly interacting with HSECP or by acting on components of the biological pathway in which HSECP participates.

- The term “antibody” refers to intact immunoglobulin molecules as well as to fragments 35 thereof, such as Fab, F(ab’)₂, and Fv fragments, which are capable of binding an epitopic determinant.

Antibodies that bind HSECP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired.

- 5 Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to 10 immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

- The term "antisense" refers to any composition capable of base-pairing with the "sense" 15 strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be 20 produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

- 25 The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic HSECP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

- The terms "complementary" and "complementarity" refer to the natural binding of 30 polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization 35 between the nucleic acid strands. This is of particular importance in amplification reactions, which

depend upon binding between nucleic acid strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding HSECP or fragments of HSECP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of one or more Incyte Clones and, in some cases, one or more public domain ESTs, using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
25	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
30	Glu	Asp, Gln, His
	Gly	Ala
	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
35	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
40	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

5 A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative 10 polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "fragment" is a unique portion of HSECP or the polynucleotide encoding HSECP which is 15 identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid 20 residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present 25 embodiments.

A fragment of SEQ ID NO:23-44 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:23-44, for example, as distinct from any other sequence in the same genome. A fragment of SEQ ID NO:23-44 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:23-44 from related 30 polynucleotide sequences. The precise length of a fragment of SEQ ID NO:23-44 and the region of SEQ ID NO:23-44 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-22 is encoded by a fragment of SEQ ID NO:23-44. A fragment of SEQ ID NO:1-22 comprises a region of unique amino acid sequence that specifically identifies 35 SEQ ID NO:1-22. For example, a fragment of SEQ ID NO:1-22 is useful as an immunogenic peptide

for the development of antibodies that specifically recognize SEQ ID NO:1-22. The precise length of a fragment of SEQ ID NO:1-22 and the region of SEQ ID NO:1-22 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

5 The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization
10 assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to
15 one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

20 The phrases "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

25 Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS
30 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

35 Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment

Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity at the

site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of 5 polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise 10 comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

15 *Expect: 10*

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for 20 example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

25 "Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely 30 resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized 35 after the "washing" step(s). The washing step(s) is particularly important in determining the

stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively. "Immune response" can refer to conditions associated with inflammation, trauma, immune

disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of HSECP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of HSECP which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

10 The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of HSECP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of HSECP.

15 The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

20 "Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

25 "Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

30 "Probe" refers to nucleic acid sequences encoding HSECP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target 35 polynucleotide by complementary base-pairing. The primer may then be extended along the target

DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also 5 be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for 10 example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose 15 such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer 20 selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for 25 Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping 30 Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization 35 technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to

identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence.

- 5 This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, *supra*. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter
- 10 sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

- 15 An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

- 20 The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding HSECP, or fragments thereof, or HSECP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

- 25 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

- 30 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

- 35 A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

5 "Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral
10 infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to
15 animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in
20 vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention
25 into such organisms are widely known and provided in references such as Sambrook et al. (1989),
supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-
30 1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of
35 polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding

polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

15 THE INVENTION

The invention is based on the discovery of new human secretory proteins (HSECP), the polynucleotides encoding HSECP, and the use of these compositions for the diagnosis, treatment, or prevention of cancer, inflammation, and gastrointestinal, cardiovascular, and neurological disorders.

20 Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding HSECP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each HSECP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The Incyte clones in column 5 were used to assemble the consensus nucleotide sequence of each HSECP and are useful as fragments in hybridization technologies.

25 The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; and column 6 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 6 were used to characterize each polypeptide through sequence homology and protein motifs. In column 5, the first line of each cell lists the amino acid 35 residues comprising predicted signal peptide sequences located at the amino terminus of each

HSECP. Additional identifying motifs or signatures, such as a somatomedin B signature in SEQ ID NO:16 and seven putative transmembrane domains in SEQ ID NO:18, are also listed in column 5.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding HSECP. The first column of Table 3 lists the 5 nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:23-44 and to distinguish between SEQ ID NO:23-44 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express HSECP as a fraction of total tissues expressing HSECP.

10 Column 4 lists diseases, disorders, or conditions associated with those tissues expressing HSECP as a fraction of total tissues expressing HSECP. Column 5 lists the vectors used to subclone each cDNA library. In particular, three out of four cDNA libraries which express SEQ ID NO:23 are derived from cartilage and synovia associated with joint inflammation, and four out of five cDNA libraries which express SEQ ID NO:29 are derived from intestinal tissue. Furthermore, about half of the 15 cDNA libraries expressing SEQ ID NO:34 are associated with inflammation or the hematopoietic/immune system. Likewise, about half of the cDNA libraries expressing SEQ ID NO:35 are associated with inflammation or the hematopoietic/immune system, and in particular, with inflammation of the joints. In addition, 82% of the cDNA libraries expressing SEQ ID NO:37 are derived from tissues of the nervous system. Finally, expression of SEQ ID NO:39 is detected solely 20 in a subtracted prostate tumor cDNA library, and expression of SEQ ID NO:43 is detected only in two cDNA libraries derived from heart tissue.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding HSECP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 25 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The invention also encompasses HSECP variants. A preferred HSECP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the HSECP amino acid sequence, and which contains at least one functional or structural characteristic of HSECP.

30 The invention also encompasses polynucleotides which encode HSECP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:23-44, which encodes HSECP. The polynucleotide sequences of SEQ ID NO:23-44, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the 35 sugar backbone is composed of ribose instead of deoxyribose.

- The invention also encompasses a variant of a polynucleotide sequence encoding HSECP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding HSECP. A particular aspect of the invention encompasses a variant of a 5 polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:23-44 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:23-44. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of HSECP.
- 10 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding HSECP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These 15 combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring HSECP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode HSECP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring HSECP under appropriately 20 selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HSECP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with 25 which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HSECP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode HSECP and HSECP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the 30 synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HSECP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID 35 NO:23-44 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and

G33S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of 5 the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is 10 automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Perkin-Elmer). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Perkin-Elmer), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a 15 variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding HSECP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, 20 such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown 25 sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme 30 digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries 35 (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National

Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been
5 size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze
10 the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process
15 from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof
which encode HSECP may be cloned in recombinant DNA molecules that direct expression of
20 HSECP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express HSECP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HSECP-encoding sequences for a variety of purposes including, but
25 not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

30 The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of HSECP, such as its biological or enzymatic activity or its ability
35 to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene

variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding HSECP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, HSECP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of HSECP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

In order to express a biologically active HSECP, the nucleotide sequences encoding HSECP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding HSECP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HSECP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding HSECP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding

sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used.

5 (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding HSECP and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. (See, e.g., Sambrook, J. et al. (1989) *Molecular Cloning, A*

10 *Laboratory Manual*, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding HSECP. These include, but are not limited to, microorganisms such as bacteria transformed 15 with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

20 In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding HSECP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding HSECP can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding HSECP into the vector's multiple 25 cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of HSECP are needed, e.g. for the production of 30 antibodies, vectors which direct high level expression of HSECP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of HSECP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such 35 vectors direct either the secretion or intracellular retention of expressed proteins and enable

integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

- Plant systems may also be used for expression of HSECP. Transcription of sequences 5 encoding HSECP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.)
10 These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HSECP may be ligated into 15 an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses HSECP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.
20

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 25 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of HSECP in cell lines is preferred. For example, sequences encoding HSECP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector.
30 Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

35 Any number of selection systems may be used to recover transformed cell lines. These

include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* and *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding HSECP is inserted within a marker gene sequence, transformed cells containing sequences encoding HSECP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HSECP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding HSECP and that express HSECP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of HSECP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HSECP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana

Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HSECP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HSECP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding HSECP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HSECP may be designed to contain signal sequences which direct secretion of HSECP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "pro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity.

Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HSECP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric HSECP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of HSECP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST),

- maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity
- 5 purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the HSECP encoding sequence and the heterologous protein sequence, so that HSECP may be cleaved away from the heterologous moiety following purification.
- Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10).
- 10 A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled HSECP may be achieved *in vitro* using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the

15 T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ^{35}S -methionine.

Fragments of HSECP may be produced not only by recombinant means, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, *supra*, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be

20 achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of HSECP may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of HSECP and human secretory proteins. In addition, the expression of HSECP is

25 closely associated with cancer, inflammation, and gastrointestinal, cardiovascular, and neurological disorders. Therefore, HSECP appears to play a role in cancer, inflammation, and gastrointestinal, cardiovascular, and neurological disorders. In the treatment of disorders associated with increased HSECP expression or activity, it is desirable to decrease the expression or activity of HSECP. In the treatment of disorders associated with decreased HSECP expression or activity, it is desirable to

30 increase the expression or activity of HSECP.

Therefore, in one embodiment, HSECP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HSECP. Examples of such disorders include, but are not limited to, a cancer such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in

35 particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall

bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma,

5 atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's

10 thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal

15 circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis,

20 pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic

25 encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha₁-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatitis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; a

30 cardiovascular disorder, and in particular, a disorder of the heart such as congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus

35 erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart

disease, congenital heart disease, and complications of cardiac transplantation; and a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural

- 5 muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the
10 nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic,
15 endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder.

In another embodiment, a vector capable of expressing HSECP or a fragment or derivative
20 thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HSECP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified HSECP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HSECP including, but not
25 limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of HSECP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of HSECP including, but not limited to, those listed above.

In a further embodiment, an antagonist of HSECP may be administered to a subject to treat or
30 prevent a disorder associated with increased expression or activity of HSECP. Examples of such disorders include, but are not limited to, those cancer, inflammation, and gastrointestinal, cardiovascular, and neurological disorders described above. In one aspect, an antibody which specifically binds HSECP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express HSECP.

35 In an additional embodiment, a vector expressing the complement of the polynucleotide

encoding HSECP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of HSECP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of HSECP may be produced using methods which are generally known in the art. In particular, purified HSECP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind HSECP. Antibodies to HSECP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with HSECP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to HSECP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HSECP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to HSECP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and

Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc.

- 5 Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HSECP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g.,

10 Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

- 15 Antibody fragments which contain specific binding sites for HSECP may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D.
- 20 et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between HSECP and its 25 specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HSECP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for HSECP. Affinity is expressed as an 30 association constant, K_a, which is defined as the molar concentration of HSECP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple HSECP epitopes, represents the average affinity, or avidity, of the antibodies for HSECP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific 35 for a particular HSECP epitope, represents a true measure of affinity. High-affinity antibody

preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the HSECP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of HSECP,

5 preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J.E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For 10 example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of HSECP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

15 In another embodiment of the invention, the polynucleotides encoding HSECP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding HSECP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HSECP. Thus, complementary molecules or 20 fragments may be used to modulate HSECP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding HSECP.

25 Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding HSECP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

30 Genes encoding HSECP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding HSECP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of 35 the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding HSECP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may be employed.

- 5 Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco 10 NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, 15 engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HSECP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, 20 corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared 25 by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding HSECP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA 30 constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible 35 modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs

and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutoxine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

5 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat.

10 Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical
15 or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HSECP, antibodies to HSECP, and mimetics, agonists, antagonists, or inhibitors of HSECP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including,
20 but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal,
25 enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's
30 Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

35 Pharmaceutical preparations for oral use can be obtained through combining active

compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, 5 hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar 10 solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of 15 gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

20 Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily 25 injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

30 For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

35 The pharmaceutical composition may be provided as a salt and can be formed with many

acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HSECP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HSECP or fragments thereof, antibodies of HSECP, and agonists, antagonists or inhibitors of HSECP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular

formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.

- 5 Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind HSECP may be used for the 10 diagnosis of disorders characterized by expression of HSECP, or in assays to monitor patients being treated with HSECP or agonists, antagonists, or inhibitors of HSECP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics.

Diagnostic assays for HSECP include methods which utilize the antibody and a label to detect 15 HSECP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring HSECP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of HSECP expression.

20 Normal or standard values for HSECP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to HSECP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of HSECP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values.
25 Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HSECP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect 30 and quantify gene expression in biopsied tissues in which expression of HSECP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of HSECP, and to monitor regulation of HSECP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding HSECP or closely related molecules may be used to identify nucleic acid sequences which encode HSECP. The specificity of the probe, whether it is 35 made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a

conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding HSECP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the HSECP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:23-44 or from genomic sequences including promoters, enhancers, and introns of the HSECP gene.

Means for producing specific hybridization probes for DNAs encoding HSECP include the cloning of polynucleotide sequences encoding HSECP or HSECP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding HSECP may be used for the diagnosis of disorders associated with expression of HSECP. Examples of such disorders include, but are not limited to, a cancer such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea,

emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis,

5 Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha - antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein

10 obstruction and thrombosis, centrilobular necrosis, peliosis hepatitis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias; adenomas, and carcinomas; a cardiovascular disorder, and in particular, a disorder of the heart such as congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease,

15 degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; and a neurological

20 disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess,

25 suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central

30 nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic

neuralgia, and Tourette's disorder. The polynucleotide sequences encoding HSECP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered HSECP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding HSECP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding HSECP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding HSECP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of HSECP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding HSECP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding HSECP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding HSECP, or a fragment of a polynucleotide complementary to the polynucleotide encoding HSECP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

Methods which may also be used to quantify the expression of HSECP include radiolabeling or biotinylation nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding HSECP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the

Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding HSECP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

5 In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not 10 known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, 15 R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, HSECP, its catalytic or immunogenic fragments, or 20 oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between HSECP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds 25 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with HSECP, or fragments thereof, and washed. Bound HSECP is then detected by methods well known in the art. Purified HSECP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a 30 solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HSECP specifically compete with a test compound for binding HSECP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HSECP.

35 In additional embodiments, the nucleotide sequences which encode HSECP may be used in

any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding 5 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

Without further elaboration, it is believed that one skilled in the art can, using the preceding 10 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/123,117, are hereby expressly incorporated by reference.

15 **EXAMPLES**

I. **Construction of cDNA Libraries**

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a 20 monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated 25 using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA 30 libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the 35 appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-

1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), pcDNA2.1 plasmid 5 (Invitrogen, Carlsbad CA), or pINCY plasmid (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids were recovered from host cells by *in vivo* excision using the UNIZAP vector system 10 (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or 15 without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically 20 using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSCAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 25 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides 30 were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques 35 disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, 5 programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO 10 software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

15 The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire 20 annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying 25 against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

30 The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:23-44. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

IV. Northern Analysis

35 Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs

from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This 5 analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

- 10 The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.
- 15 The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding HSECP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, 20 cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of HSECP Encoding Polynucleotides

25 The full length nucleic acid sequences of SEQ ID NO:23-44 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

35 High fidelity amplification was obtained by PCR using methods well known in the art. PCR

was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM

BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:23-44 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

5 **VI. Labeling and Use of Individual Hybridization Probes**

Hybridization probes derived from SEQ ID NO:23-44 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06
10 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based
15 hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature
20 under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array
25 elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and
30 patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software
35 well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or

fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al.

- 5 (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

VIII. Complementary Polynucleotides

Sequences complementary to the HSECP-encoding sequences, or any parts thereof, are used 10 to detect, decrease, or inhibit expression of naturally occurring HSECP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of HSECP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence 15 and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the HSECP-encoding transcript.

IX. Expression of HSECP

Expression and purification of HSECP is achieved using bacterial or virus-based expression 20 systems. For expression of HSECP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).
25 Antibiotic resistant bacteria express HSECP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of HSECP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding HSECP by either homologous recombination or bacterial-mediated
30 transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3224-3227; Sandig, V. et al. (1996) *Hum. Gene Ther.*
35 7:1937-1945.)

In most expression systems, HSECP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from HSECP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10 and 16). Purified HSECP obtained by these methods can be used directly in the following activity assay.

X. Demonstration of HSECP Activity

An assay for HSECP activity measures the expression of HSECP on the cell surface. cDNA encoding HSECP is subcloned into an appropriate mammalian expression vector suitable for high levels of cDNA expression. The resulting construct is transfected into a nonhuman cell line such as NIH3T3. Cell surface proteins are labeled with biotin using methods known in the art. Immunoprecipitations are performed using HSECP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of HSECP expressed on the cell surface.

Alternatively, an assay for HSECP activity measures the amount of HSECP in secretory, membrane-bound organelles. Transfected cells as described above are harvested and lysed. The lysate is fractionated using methods known to those of skill in the art, for example, sucrose gradient ultracentrifugation. Such methods allow the isolation of subcellular components such as the Golgi apparatus, ER, small membrane-bound vesicles, and other secretory organelles. Immunoprecipitations from fractionated and total cell lysates are performed using HSECP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The concentration of HSECP in secretory organelles relative to HSECP in total cell lysate is proportional to the amount of HSECP in transit through the secretory pathway.

XI. Functional Assays

HSECP function is assessed by expressing the sequences encoding HSECP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT plasmid (Life Technologies) and pCR3.1

plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of HSECP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding HSECP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding HSECP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XII. Production of HSECP Specific Antibodies

HSECP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the HSECP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A

peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-HSECP activity by, for example, binding the peptide or HSECP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIII. Purification of Naturally Occurring HSECP Using Specific Antibodies

Naturally occurring or recombinant HSECP is substantially purified by immunoaffinity chromatography using antibodies specific for HSECP. An immunoaffinity column is constructed by covalently coupling anti-HSECP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HSECP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HSECP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HSECP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HSECP is collected.

XIV. Identification of Molecules Which Interact with HSECP

HSECP, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HSECP, washed, and any wells with labeled HSECP complex are assayed. Data obtained using different concentrations of HSECP are used to calculate values for the number, affinity, and association of HSECP with the candidate molecules.

Alternatively, molecules interacting with HSECP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989, Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	23	078811	SYNORAB01	078811H1 (SYNORAB01), 078811R6 (SYNORAB01), 078811T6 (SYNORAB01),
2	24	371156	LUNGNOT02	077182F1 (SYNORAB01), 077182R1 (SYNORAB01), 289599H1 (TMLR3DT01), 371156H1 (LUNGNOT02), 523415H1 (MMLR2DT01), 3438708F6 (PENCNOT06), 3772179F6 (BRSTNOT25), 3808004H1 (CONTTUT01)
3	25	584050	PROSNOT02	584050H1 (PROSNOT02), 1726563T6 (PROSNOT14), 1739666R6 (HIPONON01), 1856214F6 (PROSNOT18), 2305379R6 (NCANNNOT01), 2681374F6 (SINIUCT01), 4070575H1 (KIDNNNOT26), 5274539H1 (OVARDIN02), SZA101719F1, SASA02714F1
4	26	863808	BRAITUT03	851821H1 (NGANNNOT01), 863808H1 (BRAITUT03), 863808T1 (BRAITUT03), 2735728F6 (OVARNOT09)
5	27	978433	BRSTINOT02	054823R1 (FIBRNNOT01), 978433H1 (BRSTINOT02), 978433R1 (BRSTINOT02), 1867687T6 (SKINBIT01), 2503122H1 (CONNTUT01), 2532586H1 (GBLANOT02), 3411659H1 (BRSTTUS08)
6	28	1655369	PROSTUT08	746013R1 (BRAITUT01), 944864R6 (RATRNOT02), 1539790R1 (SINTTUT01), 1617847F6 (BRAITUT12), 1655369F6 (PROSTUT08), 1655369H1 (PROSTUT08), 1673290F6 (BLADNOT05), 2056840R6 (BEPINOT01), 3407992H1 (PROSTUS08), 4077365H1 (PANCNOT19), 4098012H1 (BRAITUT26)

Table 1 (cont.)

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
7	29	1703244	DUODNOT02	273878H1 (PANCSTIT03), 1632051H1 (COLNNNOT19), 1703244H1 (DUODNOT02), 4176224H1 (SINTNNOT21)
8	30	1730819	BRSTTUT08	862188R1 (BRAITUT03), 1399644F1 (BRAITUT08), 1443690F1 (THYRNNOT03), 1596446F1 (BRAINOT14), 1730819F6 (BRSTTUT08), 1730819H1 (BRSTTUT08), 2304942H1 (NGANNNOT01), 2868843H1 (THYRNNOT10), 3395457H1 (LUNGNOT28)
9	31	1757161	PITUNNOT03	864626R1 (BRAITUT03), 1231577H1 (BRAITUT01), 1395593F1 (THYRNNOT03), 1466766T1 (PANCTUT02), 1466766T6 (PANCTUT02), 1597583F6 (BRAINOT14), 1757161H1 (PITUNNOT03), 1757161R6 (PITUNNOT03), 1757161T6 (PITUNNOT03)
10	32	1976095	PANCTUT02	864976T1 (BRAITUT03), 1976095H1 (PANCTUT02), 4616101H1 (BRAITUT01), SARB01143F1, SARB01861F1, SAJA02355F1
11	33	2169991	ENDCNOT03	2169991H1 (ENDCNOT03), 2313548R3 (NGANNNOT01), 2727735T3 (OVARUT05), 3095616H1 (CERVNOT03), 3186421H1 (THYMNON04), 3493007H1 (ADRETUT07), SASA03601F1, SBCA05288F1, SEDA00157F1
12	34	2616827	GBLANOT01	2616827H1 (GBLANOT01), 4637616F6 (MYEPTXT01), 5219252H1 (BRSTNOT35)
13	35	2991370	KIDNFET02	080447R1 (SYNORAB01), 190292R1 (SYNORAB01), 192279R1 (SYNORAB01), 2724873H1 (OVARTUT05), 2991370H1 (KIDNFET02), SAUA03596F1, SAUA01525F1

Table 1 (cont.)

Polypeptide SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
14	36	3031062	TLYMNNOT05	1354027T3 (LUNGNOT09), 2889215F6 (LUNGFET04), 3031062H1 (TLYMNNOT05), SBAA04235F1, SBAA00620F1, SBAA01760F1, SBAA04365F2, SBAA01589F1
15	37	3101617	BRAINOT20	3101617H1. (BRAINOT20), 3335717F6 (BRAIFET01), SCAA04574V1, SCAA04351V1, SCAA03628V1, SCAA05459V1, SCAA01004V1
16	38	3216178	TESTNOT07	632084R6 (KIDNNNOT05), 1993593T6 (CORPNOT02), 3216178F6 (TESTNOT07), 3216178H1 (TESTNOT07), 4914242H1 (LIVRFET05)
17	39	3406803	PROSTUS08	3406803F6 (PROSTUS08), 3406803H1 (PROSTUS08), 3406803T6 (PROSTUS08)
18	40	3468066	BRAIDIT01	659544H1 (BRAINOT03), 897142R1 (BRSTNOT05), 1321038F1 (BLADNOT04), 1351888F1 (LATRTUT02), 1485695F1 (CORPNOT02), 1507666F1 (LUNGNOT14), 2953291H1 (KIDNFET01), 3468066H1 (BRAIDIT01), 4426018F6 (BRAPDIT01)
19	41	3592862	293TF5T01	941610H1 (ADRENOT03), 1288036H1 (BRAINOT11), 1687969F6 (PROSTUT10), 3592862H1 (293TF5T01)
20	42	3669422	KIDNTUT16	3669422F6 (KIDNTUT16), 3669422H1 (KIDNTUT16), 3669422T6 (KIDNTUT16), 5445503H1 (LNODNOT12)
21	43	3688740	HEAANOT01	462098R6 (LATRNOT01), 3688740H1 (HEAANOT01)
22	44	3742589	THYMNOT08	938795R1 (CERVNOT01), 1255960T1 (MENITUT03), 1530330R1 (PANCNOT04), 3742589H1 (THYMNOT08), SBOA04142D1

Table 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Potential Signal Peptides and Other Signature Sequences	Analytical Methods
1	182	S149 T151 S13		M1-S16; M1-P18	MOTIFS SPSCAN HMM
2	125	T87 S36 T78 T111	N75	M1-S37	MOTIFS SPSCAN HMM
3	320	S21 T63 S267 S300	N40	M1-G20; M1-G23	MOTIFS SPSCAN HMM
4	234	T74 S198 T210 T227 S131 T195		M1-A30; M1-G25	MOTIFS SPSCAN HMM
5	278	S64 S132 S230 T252	N221	M1-A65	MOTIFS SPSCAN HMM
6	136	S98 S99		M1-P54	MOTIFS SPSCAN HMM
7	109	T57		M1-T20	MOTIFS SPSCAN HMM

Table 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Potential Peptides and Other Signature Sequences	Potential Signal Sequences	Analytical Methods
8	262	S73 S91 S136 S86	N182	M1-A25; M1-G27	MOTIFS SPSCAN HMM	
9	384	S11 T140 S32 S185 S232 S306 S378	N50 N59 N62 N304	M1-G31	MOTIFS SPSCAN HMM	
				Transmembrane domains: G195-A220 L74-F91 A142-T160		
10	244	T95 S110 T208 T44 S47 S53 S69 S152 T194		M1-A23	MOTIFS SPSCAN HMM	
11	326	S138 T59 S239	N129 N237	M1-G40	MOTIFS SPSCAN HMM	
12	105	S96 T24	N94	M1-A19; M1-A23	MOTIFS SPSCAN HMM	

Table 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Potential Peptides and Other Sequences	Analytical Methods
13	626	S188 S593 T61 T118 T144 S252 T275 T410 S423 S501 T506 S524 T536 S550 S28 T146 S336 T467 S583 T588		M1-G27 RGD tripeptide: R271-D273	MOTIFS SPSCAN HMM
14	296	S205 T295 S109 T165 T214 S244 S73 S225 Y236	N40 N53 N204 N281	M1-G23	MOTIFS. SPSCAN HMM
15	249	S7 T123 S233 S237 T151	N100	M1-G23; M1-A22 Transmembrane domains: T175-A193 F97-F120	MOTIFS SPSCAN HMM
16	124	S62 S109		M1-G37 Somatomedin B signature: L36-S105	MOTIFS SPSCAN HMM PROFILESCAN
17	101	T59 S67		M1-S40; M1-S28	MOTIFS SPSCAN HMM

Table 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Potential Peptides and Other Signature Sequences	Potential Signal Sequences	Analytical Methods
18	540	S42 S38 T80 T172 S179 S326 S519 S531 T131 T250 T278 Y99	N78 N88 N170 N347 N448 N457	M1-C29; M1-I31	MOTIFS SPSCAN HMM PRINTS	Transmembrane domains: V307-N327 L411-I428 A140-L163 D366-I385 Y99-Y122 F496-C513 I56-Y73
19	108	S34 S64 S29 S47 Y96		M1-R22; M1-S23	MOTIFS SPSCAN HMM	
20	114	S108 S5 S73 T85		M1-T32	MOTIFS SPSCAN HMM	
21	114	T8	N6	M1-A34	MOTIFS SPSCAN HMM	
22	287	S25 T75 T134 T139 S225 T255 S254		M1-P20; M1-A22	MOTIFS SPSCAN HMM	RGD tripeptide: R172-D174

Table 3

Nucleotide SEQ ID NO:	Selected Fragment(s)	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
23 110-154 542-586	Musculoskeletal (0.750) Reproductive (0.250)	Inflammation (0.750) Cancer (0.250)	PBLUESCRIPT	
24 230-271	Reproductive (0.333) Musculoskeletal (0.190) Cardiovascular (0.143)	Cancer (0.476) Inflammation (0.333)	PBLUESCRIPT	
25 109-153 649-693	Reproductive (0.314) Nervous (0.235) Gastrointestinal (0.157)	Cancer (0.608) Inflammation (0.196) Cell Proliferation (0.118)	PSPORT1	
26 116-160	Reproductive (0.333) Nervous (0.178) Cardiovascular (0.156)	Cancer (0.600) Cell Proliferation (0.178) Inflammation (0.133)	PSPORT1	
27 228-272	Reproductive (0.333) Cardiovascular (0.244) Gastrointestinal (0.111)	Cancer (0.667) Cell Proliferation (0.133) Inflammation (0.089)	PSPORT1	
28 1945-1989	Nervous (0.301) Reproductive (0.219) Gastrointestinal (0.137)	Cancer (0.452) Inflammation (0.205) Trauma (0.164)	PINCY	
29 271-315	Gastrointestinal (0.800) Nervous (0.200)	Trauma (0.600) Cancer (0.200) Inflammation (0.200)	PINCY	
30 218-262	Reproductive (0.249) Nervous (0.195) Gastrointestinal (0.136)	Cancer (0.521) Inflammation (0.207) Cell Proliferation (0.172)	PINCY	

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragment(s)	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
31	1190-1234	Nervous (0.324) Reproductive (0.250) Hematopoietic/Immune (0.118)	Cancer (0.426) Inflammation (0.279) Cell Proliferation (0.147)	PSPORT1
32	487-531	Gastrointestinal (0.333) Nervous (0.259) Reproductive (0.111)	Cancer (0.593) (0.148) Cell Proliferation (0.111)	PINCY
33	1513-1557	Reproductive (0.255) Nervous (0.216) Hematopoietic/Immune (0.176)	Cancer (0.373) Inflammation (0.255) Cell Proliferation (0.196)	PINCY
34	270-317	Hematopoietic/Immune (0.455) Musculoskeletal (0.182) Nervous (0.182)	Inflammation (0.545) Cancer (0.273) Cell Proliferation (0.091)	PINCY
35	1299-1343 1956-2000	Musculoskeletal (0.519) Nervous (0.148) Cardiovascular (0.111)	Inflammation (0.481) Cancer (0.296) Trauma (0.074)	PINCY
36	651-695	Nervous (0.250) Developmental (0.167) Gastrointestinal (0.167)	Cell Proliferation (0.667) Inflammation (0.250) Cancer (0.167)	PINCY
37	218-262	Nervous (0.818) Gastrointestinal (0.091) Reproductive (0.091)	Cancer (0.545) Cell Proliferation (0.091) Inflammation (0.091)	PINCY
38	290-334	Hematopoietic/Immune (0.250) Urologic (0.250) Developmental (0.125)	Cell Proliferation (0.375) Inflammation (0.250) Cancer (0.125)	PINCY

Table 3 (cont.)

Nucleotide SEQ ID NO:	Selected Fragment(s)	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
39	434-478	Reproductive (1.000)	Cancer (1.000)	PINCY
40	326-370	Nervous (0.242) Reproductive (0.220) Gastrointestinal (0.121)	Cancer (0.462) Inflammation (0.280) Cell Proliferation (0.121)	PINCY
41	165-209	Nervous (0.333) Gastrointestinal (0.200) Cardiovascular (0.133)	Cancer (0.467) Cell Proliferation (0.200) Inflammation (0.133)	PINCY
42	273-317	Hematopoietic/Immune (0.312) Nervous (0.188) Reproductive (0.167)	Cancer (0.354) Inflammation (0.312) Cell Proliferation (0.146)	PINCY
43	273-317	Cardiovascular (1.000)	Inflammation (0.500)	PINCY
44	435-479	Reproductive (0.297) Nervous (0.217) Gastrointestinal (0.109)	Cancer (0.464) Cell Proliferation (0.196) Inflammation (0.167)	PINCY

Table 4

Nucleotide SEQ ID NO:	Library	Library Description
23	SYNORAB01	This library was constructed using RNA isolated from the synovial membrane tissue of a 68-year-old Caucasian female with rheumatoïd arthritis.
24	LUNGNOT02	This library was constructed using RNA isolated from the lung tissue of a 47-year-old Caucasian male who died of a subarachnoid hemorrhage.
25	PROSNOT02	This library was constructed using RNA isolated from diseased prostate tissue removed from a 50-year-old Caucasian male during a retropubic prostatectomy. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated adenocarcinoma Gleason grade 3+3. Patient history included dysuria, carcinoma in situ of prostate, coronary atherosclerosis, and hyperlipidemia.
26	BRAITUT03	This library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 17-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a grade 4 fibrillary giant and small-cell astrocytoma. Family history included benign hypertension and cerebrovascular disease.
27	BRSTNOT02	This library was constructed using RNA isolated from diseased breast tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated proliferative fibrocystic changes characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia. Pathology for the associated tumor tissue indicated an invasive grade 4 mammary adenocarcinoma. Patient history included atrial tachycardia and a benign neoplasm. Family history included cerebrovascular disease.

Table 4 (cont.)

Nucleotide SEQ ID NO:	Library	Library Description
28	PROSTUT08	This library was constructed using RNA isolated from prostate tumor tissue removed from a 60-year-old Caucasian male during radical prostatectomy and regional lymph node excision. Pathology indicated an adenocarcinoma (Gleason grade 3+4). Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Patient history included a kidney cyst, and hematuria. Family history included tuberculosis, cerebrovascular disease, and arteriosclerotic coronary artery disease.
29	DUODNOT02	This library was constructed using RNA isolated from duodenal tissue of an 8-year-old Caucasian female, who died from head trauma. Serology was positive for cytomegalovirus (CMV).
30	BRSTTUT08	This library was constructed using RNA isolated from breast tumor tissue removed from a 45-year-old Caucasian female during unilateral extended simple mastectomy. Pathology indicated invasive nuclear grade 2-3 adenocarcinoma, ductal type, with 3 of 23 lymph nodes positive for metastatic disease. Greater than 50% of the tumor volume was <i>in situ</i> , both comedo and non-comedo types. Immunostains were positive for estrogen/progesterone receptors, and uninvolved tissue showed proliferative changes. The patient concurrently underwent a total abdominal hysterectomy. Patient history included valvuloplasty of mitral valve without replacement, rheumatic mitral insufficiency, and rheumatic heart disease. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
31	PITUNOT03	This library was constructed using RNA isolated from pituitary tissue of a 46-year-old Caucasian male who died from colon cancer.
32	PANCTUT02	This library was constructed using RNA isolated from pancreatic tumor tissue removed from a 45-year-old Caucasian female during radical pancreaticoduodenectomy. Pathology indicated a grade 4 anaplastic carcinoma. Family history included benign hypertension, hyperlipidemia and atherosclerotic coronary artery disease.

Table 4 (cont.)

Nucleotide SEQ ID NO:	Library	Library Description
33	ENDCN0T03	This library was constructed using RNA isolated from dermal microvascular endothelial cells removed from a neonatal Caucasian male.
34	GBLANOT01	This library was constructed using RNA isolated from diseased gallbladder tissue removed from a 53-year-old Caucasian female during a cholecystectomy. Pathology indicated mild chronic cholecystitis and cholelithiasis with approximately 150 mixed gallstones. Family history included benign hypertension.
35	KIDNFET02	This library was constructed using RNA isolated from kidney tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation.
36	TLYMN0T05	This library was constructed using RNA isolated from nonactivated Th2 cells. The cells were differentiated from umbilical cord CD4 T cells with IL-4 in the presence of anti-IL-12 antibodies and B7-transfected COS cells.

Table 4 (cont.)

Nucleotide SEQ ID NO:	Library	Library Description
37	BRAINOT20	This library was constructed using RNA isolated from diseased brain tissue removed from the left temporal lobe of a 27-year-old Caucasian male during a brain lobectomy. Pathology for the left temporal lobe, including the mesial temporal structures, indicated focal, marked pyramidal cell loss and gliosis in hippocampal sector CA1, consistent with mesial temporal sclerosis. The left frontal lobe showed a focal deep white matter lesion, characterized by marked gliosis, calcifications, and hemosiderin-laden macrophages, consistent with a remote perinatal injury. This frontal lobe tissue also showed mild to moderate generalized gliosis, predominantly subpial and subcortical, consistent with chronic seizure disorder. GFAP was positive for astrocytes. Family history included brain cancer.
38	TESTNOT07	This library was constructed using RNA isolated from testicular tissue removed from a 31-year-old Caucasian male during a unilateral orchectomy (excision of testis). Pathology indicated a mass containing a large subcapsular hematoma with laceration of the tunica albuginea. The surrounding testicular parenchyma was extensively necrotic. The patient presented with a trunk injury.
39	PROSTUS08	This subtracted library was constructed using 2.36 million clones from a prostate tumor library and was subjected to one round of subtractive hybridization with 448,000 clones from a prostate library. The starting library for subtraction was constructed using RNA isolated from a prostate tumor removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenocarcinoma (Gleason grade 3+3) and adenofibromatous hyperplasia. The patient presented with elevated prostate-specific antigen (PSA). Patient history included colon diverticuli, asbestos, and thrombophlebitis. Family history included multiple myeloma, hyperlipidemia, and rheumatoid arthritis. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR (1991) 19:1954 and Bonaldo, et al. Genome Research (1996) 6:791.
40	BRAIDIT01	This library was constructed using RNA isolated from diseased brain tissue. Patient history included multiple sclerosis, type II lesion.

Table 4 (cont.)

Nucleotide SEQ ID NO:	Library	Library Description
41	293TF5T01	This library was constructed using RNA isolated from a transformed embryonal cell line (293-EBNA) derived from kidney epithelial tissue transfected with bgal. The cells were transformed with adenovirus 5 DNA.
42	KIDNTUT16	This library was constructed using RNA isolated from left pole kidney tumor tissue removed from a 53-year-old Caucasian female during a nephroureterectomy. Pathology indicated grade 2 renal cell carcinoma. Patient history included hyperlipidemia, cardiac dysrhythmia, menorrhagia, cerebrovascular disease, atherosclerotic coronary artery disease, and tobacco abuse. Family history included cerebrovascular disease and atherosclerotic coronary artery disease.
43	HEAANOT01	This library was constructed using RNA isolated from right coronary and right circumflex coronary artery tissue removed from the explanted heart of a 46-year-old Caucasian male during a heart transplantation. Patient history included myocardial infarction from total occlusion of the left anterior descending coronary artery, atherosclerotic coronary artery disease, hyperlipidemia, myocardial ischemia, dilated cardiomyopathy, left ventricular dysfunction, and tobacco abuse. Previous surgeries included cardiac catheterization. Family history included atherosclerotic coronary artery disease.
44	THYMN0T08	This library was constructed using RNA isolated from thymus tissue removed from a 4-month-old Caucasian male during a total thymectomy and open heart repair of atrioventricular canal defect using hypothermia. Patient presented with a congenital heart anomaly, congestive heart failure, and Down syndrome. Patient history included abnormal thyroid function study, premature birth, and right and left heart angiography.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	<i>ESTs:</i> Probability value= 1.0E-8 or less <i>Full Length sequences:</i> Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-93; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	<i>ESTs:</i> fasta E value=1.06E-6 <i>Assembled ESTs:</i> fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less <i>Full Length sequences:</i> fastx score=100 or greater
BLIMPS	A BLock IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Normalized quality score > GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielsen, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. ^{supra} ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-22,
b) a naturally occurring amino acid sequence having at least 90% sequence identity to an
amino acid sequence selected from the group consisting of SEQ ID NO:1-22,
c) a biologically active fragment of an amino acid sequence selected from the group
consisting of SEQ ID NO:1-22, and
10 d) an immunogenic fragment of an amino acid sequence selected from the group consisting
of SEQ ID NO:1-22.

2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-
22.

15 3. An isolated polynucleotide encoding a polypeptide of claim 1.

4. An isolated polynucleotide of claim 3 selected from the group consisting of SEQ ID
NO:23-44.

20 5. A recombinant polynucleotide comprising a promoter sequence operably linked to a
polynucleotide of claim 3.

6. A cell transformed with a recombinant polynucleotide of claim 5.

25 7. A transgenic organism comprising a recombinant polynucleotide of claim 5.

8. A method for producing a polypeptide of claim 1, the method comprising:

30 a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said
cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide
comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of
claim 1, and
b) recovering the polypeptide so expressed.

35 9. An isolated antibody which specifically binds to a polypeptide of claim 1.

10. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44,
- b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a
- 5 polynucleotide sequence selected from the group consisting of SEQ ID NO:23-44,
- c) a polynucleotide sequence complementary to a),
- d) a polynucleotide sequence complementary to b), and
- e) an RNA equivalent of a)-d).

10 11. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 10.

12. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

15 a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if

20 present, the amount thereof.

13. A method of claim 12, wherein the probe comprises at least 30 contiguous nucleotides.

14. A method of claim 12, wherein the probe comprises at least 60 contiguous nucleotides.

25 15. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

16. A method for treating a disease or condition associated with decreased expression of
30 functional HSECP, comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 15.

17. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

35 a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting agonist activity in the sample.

18. A pharmaceutical composition comprising an agonist compound identified by a method of claim 17 and a pharmaceutically acceptable excipient.

5

19. A method for treating a disease or condition associated with decreased expression of functional HSECP, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 18.

10 20. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

15 21. A pharmaceutical composition comprising an antagonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with overexpression of functional HSECP, comprising administering to a patient in need of such treatment a pharmaceutical composition of claim 21.

25 23. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 4, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, and
- b) detecting altered expression of the target polynucleotide.

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

TANG, Y. Tom
LAL, Preeti
BAUGHN, Mariah R.
YUE, Henry
AU-YOUNG, Janice
LU, Dyung Aina M.
AZIMZAI, Yalda

<120> HUMAN SECRETORY PROTEINS

<130> PF-0675 PCT

<140> To Be Assigned
<141> Herewith

<150> 60/123,117
<151> 1999-03-05

<160> 44

<170> PERL Program

<210> 1
<211> 182
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 078811CD1

<400> 1
Met Arg Ser Thr Ile Leu Leu Phe Cys Leu Leu Gly Ser Thr Arg
1 5 10 15
Ser Leu Pro Val Phe Pro Ser Leu Ser Leu Ile Pro Leu Thr Gln
20 25 30
Met Leu Thr Leu Gly Pro Asp Leu His Leu Leu Asn Pro Ala Ala
35 40 45
Gly Met Thr Pro Gly Thr Gln Thr His Pro Leu Thr Leu Gly Gly
50 55 60
Leu Asn Val Gln Gln Gln Leu His Pro His Val Leu Pro Ile Phe
65 70 75
Val Thr Gln Leu Gly Ala Pro Gly His Tyr Pro Lys Leu Arg Gly
80 85 90
Ile Ala Thr Asn Leu His Glu Pro His His Pro Phe Leu Val Pro
95 100 105
Arg Glu Ala Ser Leu Pro Thr Ser Gln Ala Gly Ala Asn Pro Asp
110 115 120
Val Gln Asp Gly Ser Leu Pro Ala Gly Gly Ala Gly Val Asn Pro
125 130 135
Ala Thr Gln Gly Thr Pro Ala Gly Arg Leu Pro Thr Pro Ser Gly
140 145 150
Thr Asp Asp Asp Phe Ala Val Thr Thr Pro Ala Gly Ile Gln Arg
155 160 165
Ser Thr His Ala Ile Glu Glu Ala Thr Thr Glu Ser Ala Asn Gly
170 175 180
Ile Gln

<210> 2
<211> 125

<212> PRT

<213> Homo sapiens

<220> -

<221> misc_feature

<223> Incyte ID No: 371156CD1

<400> 2

Met	Val	Cys	Glu	Asp	Ala	Pro	Ser	Phe	Gln	Met	Ala	Trp	Glu	Ser
1					5				10				15	
Gln	Met	Ala	Trp	Glu	Arg	Gly	Pro	Ala	Leu	Leu	Cys	Cys	Val	Leu
					20				25				30	
Ser	Ala	Ser	Gln	Leu	Ser	Ser	Gln	Asp	Gln	Asp	Pro	Leu	Gly	His
					35				40				45	
Ile	Lys	Ser	Leu	Leu	Tyr	Pro	Phe	Gly	Phe	Pro	Val	Glu	Leu	Pro
					50				55				60	
Arg	Pro	Gly	Pro	Thr	Gly	Ala	Tyr	Lys	Lys	Val	Lys	Asn	Gln	Asn
					65				70				75	
Gln	Thr	Thr	Ser	Ser	Glu	Leu	Leu	Arg	Lys	Gln	Thr	Ser	His	Phe
					80				85				90	
Asn	Gln	Arg	Gly	His	Arg	Ala	Arg	Ser	Lys	Leu	Leu	Ala	Ser	Arg
					95				100				105	
Gln	Ile	Pro	Asp	Arg	Thr	Phe	Lys	Cys	Gly	Lys	Trp	Leu	Pro	Gln
					110				115				120	
Val	Pro	Ser	Pro	Val										
					125									

<210> 3

<211> 320

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 584050CD1

<400> 3

Met	Ala	Gly	Leu	Ala	Ala	Arg	Leu	Val	Leu	Leu	Ala	Gly	Ala	Ala
1					5				10				15	
Ala	Leu	Ala	Ser	Gly	Ser	Gln	Gly	Asp	Arg	Glu	Pro	Val	Tyr	Arg
					20				25				30	
Asp	Cys	Val	Leu	Gln	Cys	Glu	Glu	Gln	Asn	Cys	Ser	Gly	Gly	Ala
					35				40				45	
Leu	Asn	His	Phe	Arg	Ser	Arg	Gln	Pro	Ile	Tyr	Met	Ser	Leu	Ala
					50				55				60	
Gly	Trp	Thr	Cys	Arg	Asp	Asp	Cys	Lys	Tyr	Glu	Cys	Met	Trp	Val
					65				70				75	
Thr	Val	Gly	Leu	Tyr	Leu	Gln	Glu	Gly	His	Lys	Val	Pro	Gln	Phe
					80				85				90	
His	Gly	Lys	Trp	Pro	Phe	Ser	Arg	Phe	Leu	Phe	Phe	Gln	Glu	Pro
					95				100				105	
Ala	Ser	Ala	Val	Ala	Ser	Phe	Leu	Asn	Gly	Leu	Ala	Ser	Leu	Val
					110				115				120	
Met	Leu	Cys	Arg	Tyr	Arg	Thr	Phe	Val	Pro	Ala	Ser	Ser	Pro	Met
					125				130				135	
Tyr	His	Thr	Cys	Val	Ala	Phe	Ala	Trp	Val	Ser	Leu	Asn	Ala	Trp
					140				145				150	
Phe	Trp	Ser	Thr	Val	Phe	His	Thr	Arg	Asp	Thr	Asp	Leu	Thr	Glu
					155				160				165	
Lys	Met	Asp	Tyr	Phe	Cys	Ala	Ser	Thr	Val	Ile	Leu	His	Ser	Ile
					170				175				180	
Tyr	Leu	Cys	Cys	Val	Arg	Thr	Val	Gly	Leu	Gln	His	Pro	Ala	Val
					185				190				195	
Val	Ser	Ala	Phe	Arg	Ala	Leu	Leu	Leu	Leu	Met	Leu	Thr	Val	His

	200	205	210
Val Ser Tyr Leu	Ser Leu Ile Arg Phe	Asp Tyr Gly Tyr Asn	Leu
215	220	225	
Val Ala Asn Val	Ala Ile Gly Leu Val	Asn Val Val Trp Trp	Leu
230	235	240	
Ala Trp Cys Leu	Trp Asn Gln Arg Arg	Leu Pro His Val Arg	Lys
245	250	255	
Cys Val Val Val	Val Leu Leu Gln	Gly Leu Ser Leu Leu	Glu
260	265	270	
Leu Leu Asp Phe	Pro Pro Leu Phe Trp	Val Leu Asp Ala His	Ala
275	280	285	
Ile Trp His Ile	Ser Thr Ile Pro Val	His Val Leu Phe Phe	Ser
290	295	300	
Phe Leu Glu Asp	Asp Ser Leu Tyr Leu	Leu Lys Glu Ser Glu	Asp
305	310	315	
Lys Phe Lys Leu	Asp		
320			

<210> 4
<211> 234
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 863808CD1

	<400> 4		
Met Gly Pro Gly Gly Arg Val Ala Arg Leu Leu Ala Pro Leu Met			
1	5	10	15
Trp Arg Arg Ala Val Ser Ser Val Ala Gly Ser Ala Val Gly Ala			
20	25	30	
Glu Pro Gly Leu Arg Leu Leu Ala Val Gln Arg Leu Pro Val Gly			
35	40	45	
Ala Ala Phe Cys Arg Ala Cys Gln Thr Pro Asn Phe Val Arg Gly			
50	55	60	
Leu His Ser Glu Pro Gly Leu Glu Glu Arg Ala Glu Gly Thr Val			
65	70	75	
Asn Glu Gly Arg Pro Glu Ser Asp Ala Ala Asp His Thr Gly Pro			
80	85	90	
Lys Phe Asp Ile Asp Met Met Val Ser Leu Leu Arg Gln Glu Asn			
95	100	105	
Ala Arg Asp Ile Cys Val Ile Gln Val Pro Pro Glu Met Arg Tyr			
110	115	120	
Thr Asp Tyr Phe Val Ile Val Ser Gly Thr Ser Thr Arg His Leu			
125	130	135	
His Ala Met Ala Phe Tyr Val Val Lys Met Tyr Lys His Leu Lys			
140	145	150	
Cys Lys Arg Asp Pro His Val Lys Ile Glu Gly Lys Asp Thr Asp			
155	160	165	
Asp Trp Leu Cys Val Asp Phe Gly Ser Met Val Ile His Leu Met			
170	175	180	
Leu Pro Glu Thr Arg Glu Ile Tyr Glu Leu Glu Lys Leu Trp Thr			
185	190	195	
Leu Arg Ser Tyr Asp Asp Gln Leu Ala Gln Ile Ala Pro Glu Thr			
200	205	210	
Val Pro Glu Asp Phe Ile Leu Gly Ile Glu Asp Asp Thr Ser Ser			
215	220	225	
Val Thr Pro Val Glu Leu Lys Cys Glu			
230			

<210> 5
<211> 278
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 978433CD1

<400> 5
Met Gln Pro Ala Ala Ala Ser Glu Arg Gly Gly Ala Asp Ala Asp
1 5 10 15
His Val Pro Leu Leu Gly Leu Leu Arg Leu Gln Leu Arg Ala Ala
20 25 30
Arg Gln Pro Gly Ala Met Arg Pro Gln Gly Pro Ala Ala Ser Pro
35 40 45
Gln Arg Leu Arg Gly Leu Leu Leu Leu Leu Leu Gln Leu Pro
50 55 60
Ala Pro Ser Ser Ala Ser Glu Ile Pro Lys Gly Lys Gln Lys Ala
65 70 75
Gln Leu Arg Gln Arg Glu Val Val Asp Leu Tyr Asn Gly Met Cys
80 85 90
Leu Gln Gly Pro Ala Gly Val Pro Gly Arg Asp Gly Ser Pro Gly
95 100 105
Ala Asn Gly Ile Pro Gly Thr Pro Gly Ile Pro Gly Arg Asp Gly
110 115 120
Phe Lys Gly Glu Lys Gly Glu Cys Leu Arg Glu Ser Phe Glu Glu
125 130 135
Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser Trp Ser Ser Leu Asn
140 145 150
Tyr Gly Ile Asp Leu Gly Lys Ile Ala Glu Cys Thr Phe Thr Lys
155 160 165
Met Arg Ser Asn Ser Ala Leu Arg Val Leu Phe Ser Gly Ser Leu
170 175 180
Arg Leu Lys Cys Arg Asn Ala Cys Cys Gln Arg Trp Tyr Phe Thr
185 190 195
Phe Asn Gly Ala Glu Cys Ser Gly Pro Leu Pro Ile Glu Ala Ile
200 205 210
Ile Tyr Leu Asp Gln Gly Ser Pro Glu Met Asn Ser Thr Ile Asn
215 220 225
Ile His Arg Thr Ser Ser Val Glu Gly Leu Cys Glu Gly Ile Gly
230 235 240
Ala Gly Leu Val Asp Val Ala Ile Trp Val Gly Thr Cys Ser Asp
245 250 255
Tyr Pro Lys Gly Asp Ala Ser Thr Gly Trp Asn Ser Val Ser Arg
260 265 270
Ile Ile Ile Glu Glu Leu Pro Lys
275

<210> 6
<211> 136
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1655369CD1

<400> 6
Met Pro Pro Gly Gly Leu Gly Ala Cys Ala Val Thr Pro Ala Pro
1 5 10 15
Gly Glu Glu Arg Thr Gln Pro Gly Glu Leu Gly Gln Gly Leu His
20 25 30
Met Ala Gln Gly Gln Gln Met Leu Ala Gly Gln Leu Leu Pro Met

35	40	45
Leu Thr Leu Leu Pro Pro Ser Phe Pro Leu	Pro His Pro Thr Leu	
50	55	60
Gly Pro Arg Arg His Ala Ser Leu Thr Gln	Leu Gly Pro Ala Phe	
65	70	75
Trp Met Ala Trp Gly Arg Pro Trp Ala His	Leu Gly Pro Gly Gln	
80	85	90
Pro Leu Gly Gln Leu Trp Lys Ser Ser Val	Glu Glu His Leu Leu	
95	100	105
Ala Ala Trp Leu Gln Pro Leu Ala Leu Leu	Glu Trp Ser Leu Gly	
110	115	120
Ala Ser Ala Leu Ser Ala Leu Gly Thr Ser	His Pro Leu Gly Leu	
125	130	135
Gln		

<210> 7
<211> 109
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1703244CD1

<400> 7		
Met Leu Met Tyr Met Phe Tyr Val Leu Pro Phe Cys Gly Leu Ala		
1	5	10
Ala Tyr Ala Leu Thr Phe Pro Gly Cys Ser Trp Leu Pro Asp Trp		
20	25	30
Ala Leu Val Phe Ala Gly Gly Ile Gly Gln Ala Gln Phe Ser His		
35	40	45
Met Gly Ala Ser Met His Leu Arg Thr Pro Phe Thr Tyr Arg Val		
50	55	60
Pro Glu Asp Thr Trp Gly Cys Phe Phe Val Cys Asn Leu Leu Tyr		
65	70	75
Ala Leu Gly Pro His Leu Leu Ala Tyr Arg Cys Leu Gln Trp Pro		
80	85	90
Ala Phe Phe His Gln Pro Pro Pro Ser Asp Pro Leu Ala Leu His		
95	100	105
Lys Lys Gln His		

<210> 8
<211> 262
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1730819CD1

<400> 8		
Met Ala Ala Ala Ser Ala Gly Ala Thr Arg Leu Leu Leu Leu		
1	5	10
Leu Met Ala Val Ala Ala Pro Ser Arg Ala Arg Gly Ser Gly Cys		
20	25	30
Arg Ala Gly Thr Gly Ala Arg Gly Ala Gly Ala Glu Gly Arg Glu		
35	40	45
Gly Glu Ala Cys Gly Thr Val Gly Leu Leu Leu Glu His Ser Phe		
50	55	60
Glu Ile Asp Asp Ser Ala Asn Phe Arg Lys Arg Gly Ser Leu Leu		
65	70	75

Trp Asn Gln Gln Asp Gly Thr Leu Ser Leu Ser Gln Arg Gln Leu		
80	85	90
Ser Glu Glu Glu Arg Gly Arg Leu Arg Asp Val Ala Ala Leu Asn		
95	100	105
Gly Leu Tyr Arg Val Arg Ile Pro Arg Arg Pro Gly Ala Leu Asp		
110	115	120
Gly Leu Glu Ala Gly Gly Tyr Val Ser Ser Phe Val Pro Ala Cys		
125	130	135
Ser Leu Val Glu Ser His Leu Ser Asp Gln Leu Thr Leu His Val		
140	145	150
Asp Val Ala Gly Asn Val Val Gly Val Ser Val Val Thr His Pro		
155	160	165
Gly Gly Cys Arg Gly His Glu Val Glu Asp Val Asp Leu Glu Leu		
170	175	180
Phe Asn Thr Ser Val Gln Leu Gln Pro Pro Thr Thr Ala Pro Gly		
185	190	195
Pro Glu Thr Ala Ala Phe Ile Glu Arg Leu Glu Met Glu Gln Ala		
200	205	210
Gln Lys Ala Lys Asn Pro Gln Glu Gln Lys Ser Phe Phe Ala Lys		
215	220	225
Tyr Trp Met Tyr Ile Ile Pro Val Val Leu Phe Leu Met Met Ser		
230	235	240
Gly Ala Pro Asp Thr Gly Gly Gln Gly Gly Gly Gly Cys Gly		
245	250	255
Gly Gly Gly Ser Gly Arg		
260		

<210> 9
<211> 384
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1757161CD1

<400> 9			
Met Ala Glu Gln Thr' Tyr Ser Trp Ala Tyr Ser Leu Val Asp Ser			
1	5	10	15
Ser Gln Val Ser Thr Phe Leu Ile Ser Ile Leu Leu Ile Val Tyr			
20	25	30	
Gly Ser Phe Arg Ser Leu Asn Met Asp Phe Glu Asn Gln Asp Lys			
35	40	45	
Glu Lys Asp Ser Asn Ser Ser Gly Ser Phe Asn Gly Asn Ser			
50	55	60	
Thr Asn Asn Ser Ile Gln Thr Ile Asp Ser Thr Gln Ala Leu Phe			
65	70	75	
Leu Pro Ile Gly Ala Ser Val Ser Leu Leu Val Met Phe Phe Phe			
80	85	90	
Phe Asp Ser Val Gln Val Val Phe Thr Ile Cys Thr Ala Val Leu			
95	100	105	
Ala Thr Ile Ala Phe Ala Phe Leu Leu Leu Pro Met Cys Gln Tyr			
110	115	120	
Leu Thr Arg Pro Cys Ser Pro Gln Asn Lys Ile Ser Phe Gly Cys			
125	130	135	
Cys Gly Arg Phe Thr Ala Ala Glu Leu Leu Ser Phe Ser Leu Ser			
140	145	150	
Val Met Leu Val Leu Ile Trp Val Leu Thr Gly His Trp Leu Leu			
155	160	165	
Met Asp Ala Leu Ala Met Gly Leu Cys Val Ala Met Ile Ala Phe			
170	175	180	
Val Arg Leu Pro Ser Leu Lys Val Ser Cys Leu Leu Leu Ser Gly			
185	190	195	
Leu Leu Ile Tyr Asp Val Phe Trp Val Phe Phe Ser Ala Tyr Ile			

200	205	210
Phe Asn Ser Asn Val Met Val Lys Val	Ala Thr Gln Pro Ala	Asp
215	220	225
Asn Pro Leu Asp Val Leu Ser Arg Lys	Leu His Leu Gly Pro	Asn
230	235	240
Val Gly Arg Asp Val Pro Arg Leu Ser	Leu Pro Gly Lys Leu	Val
245	250	255
Phe Pro Ser Ser Thr Gly Ser His Phe	Ser Met Leu Gly Ile	Gly
260	265	270
Asp Ile Val Met Pro Gly Leu Leu Cys	Phe Val Leu Arg	Tyr
275	280	285
Asp Asn Tyr Lys Lys Gln Ala Ser Gly	Asp Ser Cys Gly Ala	Pro
290	295	300
Gly Pro Ala Asn Ile Ser Gly Arg Met	Gln Lys Val Ser Tyr	Phe
305	310	315
His Cys Thr Leu Ile Gly Tyr Phe Val	Gly Leu Leu Thr Ala	Thr
320	325	330
Val Ala Ser Arg Ile His Arg Ala Ala	Gln Pro Ala Leu Leu	Tyr
335	340	345
Leu Val Pro Phe Thr Leu Leu Pro Leu	Leu Thr Met Ala Tyr	Leu
350	355	360
Lys Gly Asp Leu Arg Arg Met Trp Ser	Glu Pro Phe His Ser	Lys
365	370	375
Ser Ser Ser Ser Arg Phe Leu Glu Val		
380		

<210> 10
<211> 244
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1976095CD1

<400> 10		
Met Asp Ile Leu Val Pro Leu Leu Gln	Leu Leu Val Leu Leu	Leu
1 5 10 15		
Thr Leu Pro Leu His Leu Met Ala	Leu Leu Gly Cys Trp Gln	Pro
20 25 30		
Leu Cys Lys Ser Tyr Phe Pro Tyr	Leu Met Ala Val Leu Thr	Pro
35 40 45		
Lys Ser Asn Arg Lys Met Glu Ser	Lys Lys Arg Glu Leu Phe	Ser
50 55 60		
Gln Ile Lys Gly Leu Thr Gly Ala	Ser Gly Lys Val Ala Leu	Leu
65 70 75		
Glu Leu Gly Cys Gly Thr Gly Ala	Asn Phe Gln Phe Tyr Pro	Pro
80 85 90		
Gly Cys Arg Val Thr Cys Leu Asp	Pro Asn Pro His Phe	Glu
95 100 105		
Phe Leu Thr Lys Ser Met Ala Glu	Asn Arg His Leu Gln Tyr	Glu
110 115 120		
Arg Phe Val Val Ala Pro Gly	Glu Asp Met Arg Gln Leu	Ala
125 130 135		
Gly Ser Met Asp Val Val Val Cys	Thr Leu Val Leu Cys	Ser
140 145 150		
Gln Ser Pro Arg Lys Val Leu Gln	Glu Val Arg Arg Val	Leu
155 160 165		
Pro Gly Gly Val Leu Phe Phe Trp	Glu His Val Ala Glu	Pro
170 175 180		
Gly Ser Trp Ala Phe Met Trp Gln	Gln Val Phe Glu Pro	Thr
185 190 195		
Lys His Ile Gly Asp Gly Cys Cys	Leu Thr Arg Glu Thr	Trp
200 205 210		

Asp Leu Glu Asn Ala Gln Phe Ser Glu Ile Gln Met Glu Arg Gln
 215 220 225
 Pro Pro Pro Leu Lys Trp Leu Pro Val Gly Pro His Ile Met Gly
 230 235 240
 Lys Ala Val Lys

<210> 11
<211> 326
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2169991CD1

<400> 11
 Met Arg Thr Glu Ala Gln Val Pro Ala Leu Gln Pro Pro Glu Pro
 1 5 10 15
 Gly Leu Glu Gly Ala Met Gly His Arg Thr Leu Val Leu Pro Trp
 20 25 30
 Val Leu Leu Thr Leu Cys Val Thr Ala Gly Thr Pro Glu Val Trp
 35 40 45
 Val Gln Val Arg Met Glu Ala Thr Glu Leu Ser Ser Phe Thr Ile
 50 55 60
 Arg Cys Gly Phe Leu Gly Ser Gly Ser Ile Ser Leu Val Thr Val
 65 70 75
 Ser Trp Gly Gly Pro Asn Gly Ala Gly Gly Thr Thr Leu Ala Val
 80 85 90
 Leu His Pro Glu Arg Gly Ile Arg Gln Trp Ala Pro Ala Arg Gln
 95 100 105
 Ala Arg Trp Glu Thr Gln Ser Ser Ile Ser Leu Ile Leu Glu Gly
 110 115 120
 Ser Gly Ala Ser Ser Pro Cys Ala Asn Thr Thr Phe Cys Cys Lys
 125 130 135
 Phe Ala Ser Phe Pro Glu Gly Ser Trp Glu Ala Cys Gly Ser Leu
 140 145 150
 Pro Pro Ser Ser Asp Pro Gly Leu Ser Ala Pro Pro Thr Pro Ala
 155 160 165
 Pro Ile Leu Arg Ala Asp Leu Ala Gly Ile Leu Gly Val Ser Gly
 170 175 180
 Val Leu Leu Phe Gly Cys Val Tyr Leu Leu His Leu Leu Arg Arg
 185 190 195
 His Lys His Arg Pro Ala Pro Arg Leu Gln Pro Ser Arg Thr Ser
 200 205 210
 Pro Gln Ala Pro Arg Ala Arg Ala Trp Ala Pro Ser Gln Ala Ser
 215 220 225
 Gln Ala Ala Leu His Val Pro Tyr Ala Thr Ile Asn Thr Ser Cys
 230 235 240
 Arg Pro Ala Thr Leu Asp Thr Ala His Pro His Gly Gly Pro Ser
 245 250 255
 Trp Trp Ala Ser Leu Pro Thr His Ala Ala His Arg Pro Gln Gly
 260 265 270
 Pro Ala Ala Trp Ala Ser Thr Pro Ile Pro Ala Arg Gly Ser Phe
 275 280 285
 Val Ser Val Glu Asn Gly Leu Tyr Ala Gln Ala Gly Glu Arg Pro
 290 295 300
 Pro His Thr Gly Pro Gly Leu Thr Leu Phe Pro Asp Pro Arg Gly
 305 310 315
 Pro Arg Ala Met Glu Gly Pro Leu Gly Val Arg
 320 325

<210> 12
<211> 105
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2616827CD1

<400> 12

Met	Asn	Leu	Gly	Val	Ser	Met	Leu	Arg	Ile	Leu	Phe	Leu	Leu	Asp
1						5				10				15
Val	Gly	Gly	Ala	Gln	Val	Leu	Ala	Thr	Gly	Lys	Thr	Pro	Gly	Ala
						20			25					30
Glu	Ile	Asp	Phe	Lys	Tyr	Ala	Leu	Ile	Gly	Thr	Ala	Val	Gly	Val
						35			40					45
Ala	Ile	Ser	Ala	Gly	Phe	Leu	Ala	Leu	Lys	Ile	Cys	Met	Ile	Arg
						50			55					60
Arg	His	Leu	Phe	Asp	Asp	Asp	Ser	Ser	Asp	Leu	Lys	Ser	Thr	Pro
						65			70					75
Gly	Gly	Leu	Ser	Asp	Thr	Ile	Pro	Leu	Lys	Lys	Arg	Ala	Pro	Arg
						80			85					90
Arg	Asn	His	Asn	Phe	Ser	Lys	Arg	Asp	Ala	Gln	Val	Ile	Glu	Leu
						95			100					105

<210> 13
<211> 626
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2991370CD1

<400> 13

Met	Ala	Pro	Ser	Ala	Asp	Pro	Gly	Met	Ser	Arg	Met	Leu	Pro	Phe
1						5			10					15
Leu	Leu	Leu	Leu	Trp	Phe	Leu	Pro	Ile	Thr	Glu	Gly	Ser	Gln	Arg
						20			25					30
Ala	Glu	Pro	Met	Phe	Thr	Ala	Val	Thr	Asn	Ser	Val	Leu	Pro	Pro
						35			40					45
Asp	Tyr	Asp	Ser	Asn	Pro	Thr	Gln	Leu	Asn	Tyr	Gly	Val	Ala	Val
						50			55					60
Thr	Asp	Val	Asp	His	Asp	Gly	Asp	Phe	Glu	Ile	Val	Val	Ala	Gly
						65			70					75
Tyr	Asn	Gly	Pro	Asn	Leu	Val	Leu	Lys	Tyr	Asp	Arg	Ala	Gln	Lys
						80			85					90
Arg	Leu	Val	Asn	Ile	Ala	Val	Asp	Glu	Arg	Ser	Ser	Pro	Tyr	Tyr
						95			100					105
Ala	Leu	Arg	Asp	Arg	Gln	Gly	Asn	Ala	Ile	Gly	Val	Thr	Ala	Cys
						110			115					120
Asp	Ile	Asp	Gly	Asp	Gly	Arg	Glu	Glu	Ile	Tyr	Phe	Leu	Asn	Thr
						125			130					135
Asn	Asn	Ala	Phe	Ser	Gly	Val	Ala	Thr	Tyr	Thr	Asp	Lys	Leu	Phe
						140			145					150
Lys	Phe	Arg	Asn	Asn	Arg	Trp	Glu	Asp	Ile	Leu	Ser	Asp	Glu	Val
						155			160					165
Asn	Val	Ala	Arg	Gly	Val	Ala	Ser	Leu	Phe	Ala	Gly	Arg	Ser	Val
						170			175					180
Ala	Cys	Val	Asp	Arg	Lys	Gly	Ser	Gly	Arg	Tyr	Ser	Ile	Tyr	Ile
						185			190					195
Ala	Asn	Tyr	Ala	Tyr	Gly	Asn	Val	Gly	Pro	Asp	Ala	Leu	Ile	Glu
						200			205					210
Met	Asp	Pro	Glu	Ala	Ser	Asp	Leu	Ser	Arg	Gly	Ile	Leu	Ala	Leu

215	220	225
Arg Asp Val Ala Ala Glu Ala Gly Val	Ser Lys Tyr Thr Gly	Gly
230	235	240
Arg Gly Val Ser Val Gly Pro Ile Leu	Ser Ser Ser Ala Ser	Asp
245	250	255
Ile Phe Cys Asp Asn Glu Asn Gly Pro	Asn Phe Leu Phe His	Asn
260	265	270
Arg Gly Asp Gly Thr Phe Val Asp Ala	Ala Ala Ser Ala Gly	Val
275	280	285
Asp Asp Pro His Gln His Gly Arg Gly	Val Ala Leu Ala Asp	Phe
290	295	300
Asn Arg Asp Gly Lys Val Asp Ile Val	Tyr Gly Asn Trp Asn	Gly
305	310	315
Pro His Arg Leu Tyr Leu Gln Met Ser	Thr His Gly Lys Val	Arg
320	325	330
Phe Arg Asp Ile Ala Ser Pro Lys Phe	Ser Met Pro Ser Pro	Val
335	340	345
Arg Thr Val Ile Thr Ala Asp Phe Asp	Asn Asp Gln Glu Leu	Glu
350	355	360
Ile Phe Phe Asn Asn Ile Ala Tyr Arg	Ser Ser Ser Ala Asn	Arg
365	370	375
Leu Phe Arg Val Ile Arg Arg Glu His	Gly Asp Pro Leu Ile	Glu
380	385	390
Glu Leu Asn Pro Gly Asp Ala Leu Glu	Pro Glu Gly Arg Gly	Thr
395	400	405
Gly Gly Val Val Thr Asp Phe Asp Gly	Asp Gly Met Leu Asp	Leu
410	415	420
Ile Leu Ser His Gly Glu Ser Met Ala	Gln Pro Leu Ser Val	Phe
425	430	435
Arg Gly Asn Gln Gly Phe Asn Asn Asn	Trp Leu Arg Val Val	Pro
440	445	450
Arg Thr Arg Phe Gly Ala Phe Ala Arg	Gly Ala Lys Val Val	Leu
455	460	465
Tyr Thr Lys Lys Ser Gly Ala His Leu	Arg Ile Ile Asp Gly	Gly
470	475	480
Ser Gly Tyr Leu Cys Glu Met Glu Pro	Val Ala His Phe Gly	Leu
485	490	495
Gly Lys Asp Glu Ala Ser Ser Val Glu	Val Thr Trp Pro Asp	Gly
500	505	510
Lys Met Val Ser Arg Asn Val Ala Ser	Gly Glu Met Asn Ser	Val
515	520	525
Leu Glu Ile Leu Tyr Pro Arg Asp Glu	Asp Thr Leu Gln Asp	Pro
530	535	540
Ala Pro Leu Glu Cys Gly Gln Gly Phe	Ser Gln Gln Glu Asn	Gly
545	550	555
His Cys Met Asp Thr Asn Glu Cys Ile	Gln Phe Pro Phe Val	Cys
560	565	570
Pro Arg Asp Lys Pro Val Cys Val Asn	Thr Tyr Gly Ser Tyr	Arg
575	580	585
Cys Arg Thr Asn Lys Lys Cys Ser Arg	Gly Tyr Glu Pro Asn	Glu
590	595	600
Asp Gly Thr Ala Cys Val Gly Trp Trp	Ser Pro Val Leu Lys	Ile
605	610	615
Val Thr Pro Gln Val Gly Lys Ser Leu	Gly Pro	
620	625	

<210> 14
<211> 296
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3031062CD1

<400> 14

Met	Glu	Trp	Trp	Ala	Ser	Ser	Pro	Leu	Arg	Leu	Trp	Leu	Leu	Leu
1				5					10					15
Phe	Leu	Leu	Pro	Ser	Ala	Gln	Gly	Arg	Gln	Lys	Glu	Ser	Gly	Ser
				20					25					30
Lys	Trp	Lys	Val	Phe	Ile	Asp	Gln	Ile	Asn	Arg	Ser	Leu	Glu	Asn
				35					40					45
Tyr	Glu	Pro	Cys	Ser	Ser	Gln	Asn	Cys	Ser	Cys	Tyr	His	Gly	Val
				50					55					60
Ile	Glu	Glu	Asp	Leu	Thr	Pro	Phe	Arg	Gly	Gly	Ile	Ser	Arg	Lys
				65					70					75
Met	Met	Ala	Glu	Val	Val	Arg	Arg	Lys	Leu	Gly	Thr	His	Tyr	Gln
				80					85					90
Ile	Thr	Lys	Asn	Arg	Leu	Tyr	Arg	Glu	Asn	Asp	Cys	Met	Phe	Pro
				95					100					105
Ser	Arg	Cys	Ser	Gly	Val	Glu	His	Phe	Ile	Leu	Glu	Val	Ile	Gly
				110					115					120
Arg	Leu	Pro	Asp	Met	Glu	Met	Val	Ile	Asn	Val	Arg	Asp	Tyr	Pro
				125					130					135
Gln	Val	Pro	Lys	Trp	Met	Glu	Pro	Ala	Ile	Pro	Val	Phe	Ser	Phe
				140					145					150
Ser	Lys	Thr	Ser	Glu	Tyr	His	Asp	Ile	Met	Tyr	Pro	Ala	Trp	Thr
				155					160					165
Phe	Trp	Glu	Gly	Gly	Pro	Ala	Val	Trp	Pro	Ile	Tyr	Pro	Thr	Gly
				170					175					180
Leu	Gly	Arg	Trp	Asp	Leu	Phe	Arg	Glu	Asp	Leu	Val	Arg	Ser	Ala
				185					190					195
Ala	Gln	Trp	Pro	Trp	Lys	Lys	Lys	Asn	Ser	Thr	Ala	Tyr	Phe	Arg
				200					205					210
Gly	Ser	Arg	Thr	Ser	Pro	Glu	Arg	Asp	Pro	Leu	Ile	Leu	Leu	Ser
				215					220					225
Arg	Lys	Asn	Pro	Lys	Leu	Val	Asp	Ala	Glu	Tyr	Thr	Lys	Asn	Gln
				230					235					240
Ala	Trp	Lys	Ser	Met	Lys	Asp	Thr	Leu	Gly	Lys	Pro	Ala	Ala	Lys
				245					250					255
Asp	Val	His	Leu	Val	Asp	His	Cys	Lys	Tyr	Lys	Tyr	Leu	Phe	Asn
				260					265					270
Phe	Arg	Gly	Val	Leu	Gln	Val	Ser	Gly	Leu	Asn	Thr	Ser	Ser	Cys
				275					280					285
Val	Ala	Ile	Ile	Leu	Met	Arg	Lys	Arg	Thr	Tyr				
				290					295					

<210> 15

<211> 249

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3101617CD1

<400> 15

Met	Asp	Gly	Lys	Lys	Cys	Ser	Val	Trp	Met	Phe	Leu	Pro	Leu	Val
1				5					10					15
Phe	Thr	Leu	Phe	Thr	Ser	Ala	Gly	Leu	Trp	Ile	Val	Tyr	Phe	Ile
				20					25					30
Ala	Val	Glu	Asp	Asp	Lys	Ile	Leu	Pro	Leu	Asn	Ser	Ala	Glu	Arg
				35					40					45
Lys	Pro	Gly	Val	Lys	His	Ala	Pro	Tyr	Ile	Ser	Ile	Ala	Gly	Asp
				50					55					60
Asp	Pro	Pro	Ala	Ser	Cys	Val	Phe	Ser	Gln	Val	Met	Asn	Met	Ala
				65					70					75
Ala	Phe	Leu	Ala	Leu	Val	Val	Ala	Val	Leu	Arg	Phe	Ile	Gln	Leu
				80					85					90

Lys Pro Lys Val Leu Asn Pro Trp Leu Asn Ile Ser Gly Leu Val		
95	100	105
Ala Leu Cys Leu Ala Ser Phe Gly Met Thr Leu Leu Gly Asn Phe		
110	115	120
Gln Leu Thr Asn Asp Glu Glu Ile His Asn Val Gly Thr Ser Leu		
125	130	135
Thr Phe Gly Phe Gly Thr Leu Thr Cys Trp Ile Gln Ala Ala Leu		
140	145	150
Thr Leu Lys Val Asn Ile Lys Asn Glu Gly Arg Arg Val Gly Ile		
155	160	165
Pro Arg Val Ile Leu Ser Ala Ser Ile Thr Leu Cys Val Val Leu		
170	175	180
Tyr Phe Ile Leu Met Ala Gln Ser Ile His Met Tyr Ala Ala Arg		
185	190	195
Val Gln Trp Gly Leu Val Met Cys Phe Leu Ser Tyr Phe Gly Thr		
200	205	210
Phe Ala Val Glu Phe Arg His Tyr Arg Tyr Glu Ile Val Cys Ser		
215	220	225
Glu Tyr Gln Glu Asn Phe Leu Ser Phe Ser Glu Ser Leu Ser Glu		
230	235	240
Ala Ser Glu Tyr Gln Thr Asp Gln Val		
245		

<210> 16
<211> 124
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3216178CD1

<400> 16
Met Gly Gly Tyr Leu Lys Thr Arg Pro Trp Thr Leu Gln His Phe
1 5 10 15
Tyr Leu Cys Leu Met Pro Ala Ala Thr Trp Leu Val Leu Leu Leu
20 25 30
Leu Leu Trp Leu Ser Leu Gly Val Lys Thr Gly Ser Cys Ser Gln
35 40 45
Pro Gln Asn Leu Cys Cys Leu Gly Thr Asp His His Cys Lys Arg
50 55 60
Gly Ser Cys Tyr Cys Asp Glu Phe Cys His Val Ala Pro Asp Cys
65 70 75
His Pro Asp His Ser Val Leu Cys Asn Pro Ala Ser Gln Met Thr
80 85 90
Lys Met Val Leu Gln Met Val Leu Arg Met Glu Asn Pro Pro Ser
95 100 105
Pro Ala Arg Ser His Leu Asp Trp Met Gln Ser Met Val Ser Ser
110 115 120
Leu Gln Val Leu

<210> 17
<211> 101
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3406803CD1

<400> 17

Met Leu Pro Val Gly Ala Gln Pro Arg Ser Pro Pro Trp Val Leu
 1 5 10 15
 Ala Arg Leu Leu His Pro Arg Gly Pro Ala Ala Thr Ser Leu Val
 20 25 30
 Pro Phe Leu Pro Trp Gly Ser Leu Glu Ser His Thr Pro Cys Pro
 35 40 45
 Tyr Arg Ala Cys Ser Pro Gly Trp Glu Leu Thr Leu Ser Thr Phe
 50 55 60
 Pro Glu Arg Glu Thr Leu Ser Gly Gly Glu Val Arg Lys Arg Gly
 65 70 75
 Ala Gly Ser Met Val Gly Gly Glu Ser Thr Met Thr Arg Ala
 80 85 90
 Leu Cys Val Arg Leu Leu Thr Lys Leu Arg Val
 95 100

<210> 18
<211> 540
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3468066CD1

<400> 18
 Met Ala Thr Ser Gly Ala Ala Ser Ala Glu Leu Val Ile Gly Trp
 1 5 10 15
 Cys Ile Phe Gly Leu Leu Leu Ala Ile Leu Ala Phe Cys Trp
 20 25 30
 Ile Tyr Val Arg Lys Tyr Gln Ser Arg Arg Glu Ser Glu Val Val
 35 40 45
 Ser Thr Ile Thr Ala Ile Phe Ser Leu Ala Ile Ala Leu Ile Thr
 50 55 60
 Ser Ala Leu Leu Pro Val Asp Ile Phe Leu Val Ser Tyr Met Lys
 65 70 75
 Asn Gln Asn Gly Thr Phe Lys Asp Trp Ala Asn Ala Asn Val Ser
 80 85 90
 Arg Gln Ile Glu Asp Thr Val Leu Tyr Gly Tyr Tyr Thr Leu Tyr
 95 100 105
 Ser Val Ile Leu Phe Cys Val Phe Phe Trp Ile Pro Phe Val Tyr
 110 115 120
 Phe Tyr Tyr Glu Glu Lys Asp Asp Asp Asp Thr Ser Lys Cys Thr
 125 130 135
 Gln Ile Lys Thr Ala Leu Lys Tyr Thr Leu Gly Phe Val Val Ile
 140 145 150
 Cys Ala Leu Leu Leu Leu Val Gly Ala Phe Val Pro Leu Asn Val
 155 160 165
 Pro Asn Asn Lys Asn Ser Thr Glu Trp Glu Lys Val Lys Ser Leu
 170 175 180
 Phe Glu Glu Leu Gly Ser Ser His Gly Leu Ala Ala Leu Ser Phe
 185 190 195
 Ser Ile Ser Ser Leu Thr Leu Ile Gly Met Leu Ala Ala Ile Thr
 200 205 210
 Tyr Thr Ala Tyr Gly Met Ser Ala Leu Pro Leu Asn Leu Ile Lys
 215 220 225
 Gly Thr Arg Ser Ala Ala Tyr Glu Arg Leu Glu Asn Thr Glu Asp
 230 235 240
 Ile Glu Glu Val Glu Gln His Ile Gln Thr Ile Lys Ser Lys Ser
 245 250 255
 Lys Asp Gly Arg Pro Leu Pro Ala Arg Asp Lys Arg Ala Leu Lys
 260 265 270
 Gln Phe Glu Glu Arg Leu Arg Thr Leu Lys Lys Arg Glu Arg His
 275 280 285
 Leu Glu Phe Ile Glu Asn Ser Trp Trp Thr Lys Phe Cys Gly Ala

	290		295		300
Leu Arg Pro Leu Lys Ile Val Trp Gly		Ile Phe Phe Ile Leu Val			
305		310		315	
Ala Leu Leu Phe Val Ile Ser Leu Phe		Leu Ser Asn Leu Asp Lys			
320		325		330	
Ala Leu His Ser Ala Gly Ile Asp Ser		Gly Phe Ile Ile Phe Gly			
335		340		345	
Ala Asn Leu Ser Asn Pro Leu Asn Met		Leu Leu Pro Leu Leu Gln			
350		355		360	
Thr Val Phe Pro Leu Asp Tyr Ile Leu		Ile Thr Ile Ile Ile Met			
365		370		375	
Tyr Phe Ile Phe Thr Ser Met Ala Gly		Ile Arg Asn Ile Gly Ile			
380		385		390	
Trp Phe Phe Trp Ile Arg Leu Tyr Lys		Ile Arg Arg Gly Arg Thr			
395		400		405	
Arg Pro Gln Ala Leu Leu Phe Leu Cys		Met Ile Leu Leu Leu Ile			
410		415		420	
Val Leu His Thr Ser Tyr Met Ile Tyr		Ser Leu Ala Pro Gln Tyr			
425		430		435	
Val Met Tyr Gly Ser Gln Asn Tyr Leu		Ile Glu Thr Asn Ile Thr			
440		445		450	
Ser Asp Asn His Lys Gly Asn Ser Thr		Leu Ser Val Pro Lys Arg			
455		460		465	
Cys Asp Ala Glu Ala Pro Glu Asp Gln		Cys Thr Val Thr Arg Thr			
470		475		480	
Tyr Leu Phe Leu His Lys Phe Trp Phe		Phe Ser Ala Ala Tyr Tyr			
485		490		495	
Phe Gly Asn Trp Ala Phe Leu Gly Val		Phe Leu Ile Gly Leu Ile			
500		505		510	
Val Ser Cys Cys Lys Gly Lys Lys Ser		Val Ile Glu Gly Val Asp			
515		520		525	
Glu Asp Ser Asp Ile Ser Asp Asp Glu		Pro Ser Val Tyr Ser Ala			
530		535		540	

<210> 19
<211> 108
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3592862CD1

<400> 19
Met Thr Pro Ser Arg Leu Pro Trp Leu Leu Ser Trp Val Ser Ala
1 5 10 15
Thr Ala Trp Arg Ala Ala Arg Ser Pro Leu Leu Cys His Ser Leu
20 25 30
Arg Lys Thr Ser Ser Gln Gly Gly Lys Ser Glu Leu Val Lys
35 40 45
Gln Ser Leu Lys Lys Pro Lys Leu Pro Glu Gly Arg Phe Asp Ala
50 55 60
Pro Glu Asp Ser His Leu Glu Lys Glu Pro Leu Glu Lys Phe Pro
65 70 75
Asp Asp Val Asn Pro Val Thr Lys Glu Lys Gly Gly Pro Arg Gly
80 85 90
Pro Glu Pro Thr Arg Tyr Gly Asp Trp Glu Arg Lys Gly Arg Cys
95 100 105
Ile Asp Phe

<210> 20

<211> 114
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3669422CD1

<400> 20
Met Ser Ser Ser Ser Arg Cys Leu Ser Pro Ser Pro Gly Met
1 5 10 15
Ser Leu Trp Ser Cys Leu Leu Phe Leu Cys Thr Pro Ser Pro Thr
20 25 30
Thr Thr Ser Pro Ser Pro Asp Pro Ser Gln Val Ser Thr Leu Pro
35 40 45
Thr Pro Ser Pro Gln Arg Glu Gly Leu Lys Gln Gly Gln Trp Arg
50 55 60
Lys Thr Gly Pro Ser Ser Thr His Pro His Thr Pro Ser Ser Arg
65 70 75
Pro Pro Ser Pro Ser Ser Leu Pro Leu Thr Trp Lys Leu Leu Gln
80 85 90
Pro Ile Pro Ser His Ser Leu Pro His Pro Pro Lys Ile His Thr
95 100 105
Gly Pro Ser Leu Ala Glu Cys Gly His
110

<210> 21
<211> 114
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3688740CD1

<400> 21
Met Arg Gly Glu His Asn Ser Thr Ser Tyr Asp Ser Ala Val Ile
1 5 10 15
Tyr Arg Gly Phe Trp Ala Val Leu Met Leu Leu Gly Val Val Ala
20 25 30
Val Val Ile Ala Ser Phe Leu Ile Ile Cys Ala Ala Pro Phe Ala
35 40 45
Ser His Phe Leu Tyr Lys Ala Gly Gly Ser Tyr Ile Ala Ala
50 55 60
Asp Gly Ile Ser Ser Leu Cys Tyr Ser Ser Leu Ser Lys Ser Leu
65 70 75
Leu Ser Gln Pro Leu Arg Glu Thr Ser Ser Ala Ile Asn Asp Ile
80 85 90
Ser Leu Leu Gln Ala Leu Met Pro Leu Leu Gly Trp Thr Ser His
95 100 105
Trp Thr Cys Ile Thr Val Gly Leu Tyr
110

<210> 22
<211> 287
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3742589CD1

<400> 22

Met	Glu	Leu	Glu	Arg	Ile	Val	Ser	Ala	Ala	Leu	Leu	Ala	Phe	Val
1														15
Gln	Thr	His	Leu	Pro	Glu	Ala	Asp	Leu	Ser	Gly	Leu	Asp	Glu	Val
														30
Ile	Phe	Ser	Tyr	Val	Leu	Gly	Val	Leu	Glu	Asp	Leu	Gly	Pro	Ser
														45
Gly	Pro	Ser	Glu	Glu	Asn	Phe	Asp	Met	Glu	Ala	Phe	Thr	Glu	Met
														60
Met	Glu	Ala	Tyr	Val	Pro	Gly	Phe	Ala	His	Ile	Pro	Arg	Gly	Thr
														75
Ile	Gly	Asp	Met	Met	Gln	Lys	Leu	Ser	Gly	Gln	Leu	Ser	Asp	Ala
														90
Arg	Asn	Lys	Glu	Asn	Leu	Gln	Pro	Gln	Ser	Ser	Gly	Val	Gln	Gly
														105
Gln	Val	Pro	Ile	Ser	Pro	Glu	Pro	Leu	Gln	Arg	Pro	Glu	Met	Leu
														120
Lys	Glu	Glu	Thr	Arg	Ser	Ser	Ala	Ala	Ala	Ala	Ala	Asp	Thr	Gln
														135
Asp	Glu	Ala	Thr	Gly	Ala	Glu	Glu	Leu	Leu	Pro	Gly	Val	Asp	
														150
Val	Leu	Leu	Glu	Val	Phe	Pro	Thr	Cys	Ser	Val	Glu	Gln	Ala	Gln
														165
Trp	Val	Leu	Ala	Lys	Ala	Arg	Gly	Asp	Leu	Glu	Glu	Ala	Val	Gln
														180
Met	Leu	Val	Glu	Gly	Lys	Glu	Glu	Gly	Pro	Ala	Ala	Trp	Glu	Gly
														195
Pro	Asn	Gln	Asp	Leu	Pro	Arg	Arg	Leu	Arg	Gly	Pro	Gln	Lys	Asp
														210
Glu	Leu	Lys	Ser	Phe	Ile	Leu	Gln	Lys	Tyr	Met	Met	Val	Asp	Ser
														225
Ala	Glu	Asp	Gln	Lys	Ile	His	Arg	Pro	Met	Ala	Pro	Lys	Glu	Ala
														240
Pro	Lys	Lys	Leu	Ile	Arg	Tyr	Ile	Asp	Asn	Gln	Val	Val	Ser	Thr
														255
Lys	Gly	Glu	Arg	Phe	Lys	Asp	Val	Arg	Asn	Pro	Glu	Ala	Glu	
														270
Met	Lys	Ala	Thr	Tyr	Ile	Asn	Leu	Lys	Pro	Ala	Arg	Lys	Tyr	Arg
														285
Phe	His													

<210> 23

<211> 854

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 078811CB1

<400> 23

attttgcctc	gtggacccaa	aggttagcaat	ttgaaaacatg	aggagtagcga	ttctactgtt	60
ttgtcttcta	ggatcaactc	ggtcattacc	agtctttcct	tctttaagtc	tgataccatt	120
aacacagatg	ctcacactgg	ggccagatct	gcatctgtta	aatcctgctg	caggaatgac	180
acctggtacc	cagaccccacc	cattgaccct	gggagggttg	aatgtacaac	agcaactgca	240
cccacatgt	ttaccaattt	ttgtcacaca	acttggagcc	ccagggcact	attctaagct	300
cagaggaatt	gccacaaaatc	ttcacagagcc	tcatcatcca	ttccttggtc	cccgggaggc	360
atccttgc	accagtgcagg	cagggctaa	tccagatgtc	caggatggaa	gccttccagg	420
aggaggagca	ggtgtaaatc	ctgcccccca	ggaaacccca	gcagggcc	tcccaactcc	480
cagtggcaca	gatgacgact	ttgcagtgcac	cacccctgcac	ggcatccaaa	ggagcacaca	540
tgccatcgag	gaagccacca	cagaatcagc	aaatggaatt	cagtaagctg	tttcaaattt	600
tttcaactaa	gctgcctcga	atttgggtat	acatgtgaat	ctttatcatt	gattatatta	660
tggaatagat	tgagacacat	tggatagtct	tagaagaaaat	taattcttaa	tttacctgaa	720
aatattcttg	aaatttcaga	aaatatgttc	tatgttagaga	atcccaactt	ttaaaaaacaa	780

taattcaatg gataaatctg tcttggaaat ataaacattat gctgcctgga tgatatgcat 840
 attaaaacga atta 854

<210> 24
 <211> 1804
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 371156CB1

<400> 24
 gtataggca gctttccttc tttcaacag tgatacctac gaaaatcaa ataaatgca 60
 gctgagggtt tggctcaact gaaaggcgtg tcaaccccaag aaggccgaca caaaaaaaaaat 120
 ggtatgtcaa gatgcaccgt ctttcaaat ggctgggag agtcaaattgg cctggagag 180
 ggggcctgcc ctctctgct gtgtcccttc ggctcccag ttgagctccc aagaccagga 240
 cccactgggg catataaaat ctctgtcta tccttcggc ttcccagttt agctcccaag 300
 accaggaccc actggggcat ataaaaaaagt caaaaatcaa aatcaaaca caagttctga 360
 gttacttagg aaacagactt cgccattcaa tcagagaggc cacagagcaa ggtctaaact 420
 tctggcttct agacaaattt ctgatagaac attaaatgt gggaaatggc ttccccagg 480
 cccatccccgt gtttagggat agagttgata tcatttttat aggtgcctatg tatgcctctg 540
 cctgaattttt ttaatttgac tttttaggtt ttgagattgc acgaggggaga acaaggcctt 600
 tgctgtgtg gatagggaaag acttaaccta aatattaaacc agcaagaaag catttagaaaa 660
 aatctaacaa tatgaaggc tctttagt catttttttcaaaaatggaa aactccagaa 720
 acgcacagga acgaaatacc tcccagaaac atgaagcaat catcgaaagac tcactggtaa 780
 tatttttaaa aagtatacag atcaaagcaa aaagaagcca tttgttaacaa agagaaatgt 840
 gcaaataattt ttaaggcag tattaatgc aagaggagta acatgaaata aacattctt 900
 cacatggcta ctgggatat aatattcgct ccagaaaggc cgtagcagtt tgacgatagg 960
 tggcaaaacc ttaagattgt gtactgggc ccagaattttt tatttctagg aatgtatcct 1020
 gaggaaatta tccgagatcc ccacaaactg caatgttttag gaattgtcct tatagcattg 1080
 catacacaag aaaaacagag aaaagcctga tcctgtcag tggaaaagggtt gttcaatgaa 1140
 ttacgggtg tctgcattgag gcttttatga cattaaaaat ttgttgaacaa cgccaggca 1200
 cagtgctca tggctgtat cctaacaactt tgggaggcga aggtgggaag attgcctgag 1260
 ctcaggatgt tgagggcacc ctggcaaca cgtgaaaacc cggctctctac taaaatacaa 1320
 aaaatttagcc gggcgctcgca gcatgcgcct gtatcccag ctgctcaggaa ggctgaggca 1380
 ggagaattga ttgaacccgg gaggcagagg ttgcactgag ctgagattaa gccaccgcac 1440
 tccagcctgg gcgcacaggg aagattccgt tcccaagaaa aaaaaattgt tcaacaataa 1500
 gggcaaaaggg agagaatcat aacatctgat taaacagaaaa aagcaagatt tttaaaacta 1560
 actatataag gatggtccca gctgtgtcaa aaggaagctt ttgttaata cgtgtgcata 1620
 aaaattaaat agaggtgaac acaattattt taaggcagtt aaattatctc ttttattgtga 1680
 actaagactt tctagaattt tacttattca ttctgtactt aaattttttc taatgaacac 1740
 atatactttt gtaatcagaa aatattaaat gcatgttattt ttcaaaatca aaaaaaaaaa 1800
 aaaa 1804

<210> 25
 <211> 2663
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 584050CB1

<400> 25
 ggagaaagga tggccggcct ggcggcgccg ttggctctgc tagctgggc agcggcgctg 60
 gcgagcggct cccagggcgaa ccgtgagccg gtgtaccgcg actgcgtact gcagtgca 120
 gagcagaact gctctgggg cgctctgaat cacttccgtt cccgcaccc aatctacatg 180
 agtctacatc gctggacgtg tcgggacgc tttttttttt tttttttttt tttttttttt 240
 gggctctacc tccaggaagg tcacaaatgt cttttttttt tttttttttt tttttttttt 300
 cggttctgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360
 agcctgggtga tgctctggcc ctacccgcac ttctgtccag cttttttttt tttttttttt 420
 acctgtgtgg ctttcgtccctt ggtgtccctt aatgcattgt tttttttttt tttttttttt 480
 accaggagaca ctgacccatc agagaaaaatg gactacttctt tttttttttt tttttttttt 540
 cactcaatctt acctgtgtgg ctttcgtccctt ggtgtccctt aatgcattgt tttttttttt 600

gccttccggg	cttcctgtc	gctcatgtc	accgtgcacg	tctccatct	gaggctcatc	660
cgttcgact	atggctacaa	ctgggtggcc	aacgtggcta	ttggccttgt	caacgtggtg	720
tggggctgg	cctggtgct	gtggAACAG	cgggggctgc	ctcacgtcgc	caagtgcgtg	780
gtgggtgtct	tgctgtgtca	ggggctgtcc	ctgctcgagc	tgcttgactt	cccaccgctc	840
ttctgggtcc	tggatgcccc	tgccatctgg	cacatcagca	ccatccctgt	ccacgtcctc	900
tttttcagct	ttctggaaaga	tgacagcgtc	tacctgtca	aggaatcaga	ggacaagttc	960
aagctggact	gaagaccttg	gagcgagct	gcccagttgg	ggatcctgcc	cccccctgc	1020
tggccctct	tctccctca	acccttggaa	tgatTTTCTC	ttttaaattt	tttgaacttg	1080
gacatgaagg	atggggcccc	agaatcatgt	ggcagcccc	ccccctgtt	gccttcacca	1140
gccttggagt	ctgttcttagg	gaaggcctcc	cagcatctgg	gactcgagag	tgggcagcccc	1200
ctctacccct	tggagctgaa	ctgggggtgg	actgagttgt	ttcttagctc	tacccgggagg	1260
acagctgcct	gttcctccc	caccagcctc	ctccccacat	ccccagctgc	ctggctgggt	1320
cctgaagccc	tctgtctacc	tgggagacca	gggaccacag	gccttaggga	tacagggggt	1380
ccccctctgt	taccacccccc	caccctctc	caggacacca	ctaggtgtt	ctggatgttt	1440
gttcttggc	cagccaaggt	tcacggcgat	tctccccatg	ggatcttgag	ggaccaagct	1500
gctgggattt	ggaaggaggt	tcacccctgac	cgttgcctta	gccaggttcc	caggaggccct	1560
caccatactc	ccttcagggg	ccagggctcc	agaacgcccc	gggcaaggat	cctgtgtctc	1620
tgtctgggtt	agagcctgcc	accgtgttc	gggagtgtgg	gccaggctga	gtgcataagg	1680
gacaggggcc	ttagcatggg	cctgggtgt	tgtgagtc	ggccttaggt	cgcagtgtgg	1740
agacgggtgt	tgtcggggaa	gagggtgtgc	ttcaaagtgt	gtgtgtcag	gggggtgggt	1800
tgttagcgtg	ggttagggaa	acgtgtgtc	gctgtgttgt	gggcatgtga	gatgagtgtac	1860
tgccgggtaa	tgtgtccaca	gttggagaggt	tggagcagga	tgaggaaatc	ctgtcaccat	1920
caataatcac	tttggagacg	ccagctctc	ccaaagacgcc	acctggccgg	acagccagga	1980
gctctccatg	gccaggctc	ctgtgtcat	gttccctgtc	tgggcccct	ttgcccgcct	2040
cctgcaaacc	tcacagggtc	cccacacaac	agtgcctcc	agaagcagcc	cctcggaggc	2100
agaggaagga	aatggggat	ggctgggct	cttcctcatec	tcctttctc	cttgccttcg	2160
catggctggc	cttccctcc	aaaacctcca	ttccccctgt	gccagccct	ttgccccatgc	2220
ctgatTTTGG	ggaggaggaa	ggggcgattt	gagggagaag	gggagaaagc	ttatggctgg	2280
gtctgggttc	ttcccttccc	agagggctt	actgttccag	ggggccccca	gggcaggcag	2340
ggggccacact	atgcctgcgc	cctgttaaag	gtgacccctg	ccatttacca	gcacccctgg	2400
catgttctg	ccccacagga	atagaatgga	gggagctc	gaaacttcc	atcccaaaagg	2460
cagtctccgt	ggggccccac	gactggattt	ttgtctgtcc	cctgaccctt	tgttcccttt	2520
tgagggaggg	ggttgaagca	aggactccaa	cctcaggggac	tcgggtggcc	tgcgctagct	2580
tctttgtata	ctgaaaactt	ttaagggtgg	agggtggcaa	gggatgtgct	taataaatca	2640
attccaaagcc	taaaaaaaaaa	aaa				2663

<210> 26
<211> 769
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<223> Incyte ID No: 863808CB1

<400> 26

cgacgcgcga	cgcaaggctg	ctgctatggg	gccccggcgc	cgtgtggcgc	ggctgctcgc	60
cccactaatg	tggcgaggg	cggtttctc	ggtggcgggg	tcccggttg	gagccgagcc	120
cgggcttcgg	ctgtggccg	tgcagcgct	tcccgtagga	gcagcgttct	gccgggcttg	180
ccagacccca	aaccttgtcc	gccccctgca	cagcgagcct	gggctggagg	agcgggcccga	240
ggggacggtc	aacgagggac	gccccagaatc	ggacgcggca	gatcatactg	gtcccaagtt	300
tgacatcgat	atgatggtt	cacttctgag	gcaagaaaaat	gcaagagaca	tttgggtgtat	360
ccaggttct	ccagaaaatga	gatatacaga	ttactttgtg	attgttagt	gaacttctac	420
ccgacactta	catgccccatgg	ccttctacgt	tgtaaaaatg	tacaaaacacc	tgaatgtaa	480
acgtgaccct	catgtttaaga	tagaaggcaa	ggacactgtat	gactggctgt	gcgtggattt	540
tggcagcatg	gtgattcatt	tgatgctcc	agaaaaccaga	gaaatctatg	aatttagagaa	600
attatggacc	ctacgttctt	atgatgacca	gttagctcg	atagcacctg,	agacagtacc	660
tgaagacttc	attcttggaa	tagaagatga	tacttcatct	gtgactccag	tggagttaaa	720
atgtgaataa	aatattttat	gcactgcgtt	agtaaaaaaaaa	aaaaaaaaaa		769

<210> 27
<211> 1257
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No: 978433CB1

<400> 27

```

gaggcgcgcg ggtgaaaggc gcattgatgc agccctgcggc ggcctcgag cgcggcggag  60
cagacgtga ccacgttctt ctcctcggtc tcctccggct ccagctccgc gctgcccggc 120
agccgggagc catgcgaccc cagggccccg ccgcctcccc gcagcggctc cgccggcctcc 180
tgctgctcct gctgctgcag ctgcccggc cgtcgagcgc ctctgagatc cccaaggggga 240
agcaaaaaggc gcagctccgg cagagggagg tggtgaccc gtataatggaa atgtgcttac 300
aagggccagc aggagtgcct ggtcgagacg ggagccctgg ggccaatggc attccgggta 360
cacctggat cccaggtcgg gatggattca aaggagaaaa gggggaatgt ctgagggaaa 420
gctttgagga gtcctggaca cccaactaca agcagtgttc atggagttca ttgaattatg 480
gcatagatct tggaaaattt gccggagtgtt catttacaaa gatgcgttca aatagtgtctc 540
taagagtttt gttcagtggc tcacttcggc taaaatgcag aaatgcatgc tgcagcggt 600
gttatttcac attcaatggaa gctgaatgtt caggacctt tcccatggaa gctataattt 660
atttggacca aggaaggccctt gaaaatgattt caacaattaa tatttcatgcg acttcttctg 720
tggaggact ttgtgaaggg attgggtgctt gatttagtggaa tggtgctatc tgggttggca 780
cttggccaga ttacccaaaaa ggagatgtt ctaactggatg gaattcagtt ttcgcgtatca 840
ttatttgaaga actacccaaaaa taaaatgtttt aattttcatt tgctacccctt ttttttatta 900
tgccttggaa tggttactt aaatgacatt taaaataatgtt ttatgtatc atctgaatga 960
aaagcaaaagc taaaatatgtt tacagacccaa agtgtgattt cacactgttt taaaatctag 1020
cattattcat tttgcttcaa tccaaatgtgg ttcaatattt ttttttagttt gtttagaata 1080
cttcttcattt agtcacatcc tctcaaccta taatttggaa tattttgttgc gttttttgtt 1140
ttttctttaa gtatagcattttt ttttttttttataatgtttt accaatctt gtaaaaaattt 1200
taaatgttaa gaattttttt ttttttttttataatgtttt aaaaaaaaaat ttttccaac aacctta 1257

```

<210> 28
<211> 2560
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1655369CB1

<400> 28

```

ttccagtgaa gagcaagtgc tgcccgaccc aggaccctgt gccaggctag cagccctcca  60
gctccctcca gagaggaaac ctctgtctgg ctgaggggtgg gactagctgg gatgtctcac 120
tccagttgtt caggttccacc caggaagctc ctccgtggag tggccagctt gattcttagcc 180
ctgtcccttc tggcagcaca tgccacaccc gcttggccct tctgctccctt gatgtttgt 240
gagccctgc ctctctcaatg tttctcaag acagacccccc ctgaggccag ctgtatgtt 300
aagactgtg aagtctgtt gcttcaactt gactgcagaa aaggtggctg ggtatggccca 360
ggtcacccca gaggccccccg ccctttggct gccttgggt tttgtatgg tttgtctctg 420
aggccctggc agagctggc ctgcgggtgg tggcgggtcc gacccctggc agtcagtgtt 480
ccgcagcctc agcaactgtt cccagacccca gtgtccctcaag agggaaagagc cagccctccct 540
gcctcatggaa accaggagtc cccaaaaatgtt aggagccctgg aggctctgaa aggagcagg 600
attccatagt gctgttggat gaaataggcg ccctcttggg gagcccccag caaaactgtt 660
tttcataccccc actcccaagaa ctgccccgtt ccagctccag ccgcagcgtcc agctgggttgc 720
caggcgtcat tggagaggcc tggctggccc agggcagca gggagtgggt gacctgtatg 780
ggctggcagg aggccattgg ccatgttgcg aagtgttgc tgccttctca gcctggagcc 840
acccttcagg tggctgttgc gcaccttctca tccggaggtt gcctggccca cctgttaggca 900
gaggggggctt tggcttggagg cctgcacagg aagcaagatg agccccgggtt ccccaagatgtt 960
ggttccactt agccctggcg agatggcttgc tcctgatgtt tctgttccca gaccccaacca 1020
tctggggagc acatgttcttgc ggcgttgcgg tccaggaaagg ggggtgggtt ctgtcaggaa 1080
acctggactc tcaaggccca ccagcccttc cgtgttgc ttttttttttataatgtttt gatacagtat 1140
atacttaattt acactaaattt attgttggaa ttcccttataat gcaactaattt tacctgttata 1200
taggttaaaa ttttttttttataatgtttt gcaaaaatattt ttcccttggaa atgttggat ttttttttttataatgtttt 1260
gttcattgtt gctgagatgtt gaaaactaac cattcccttc tgccttaccc ttttttttttataatgtttt 1320
gggcggcaga gaatggcgctt atgttgcgtt gggccctgg caccatggc ctttggccctg 1380
cctgttgcgtt agtagccctgtt cttggccgtt ctccaggccat tgagcaggcc atctgtggcc 1440
aggctgagatg aatgtactggc tcgttccatca gctgttgcgtt gacaaggagc ttttttttttataatgtttt 1500
caagggggttt tggcttggctt gggcttaggg gaaagggttgc catccgttgc tcccttgcgtt 1560
tttttttttataatgtttt gggcttaggg gaaagggttgc catccgttgc tcccttgcgtt 1620
cccaccatgc cacctgggtgg ttttttttttataatgtttt gggcttaggg gaaagggttgc catccgttgc tcccttgcgtt 1680
aggacccaccc cccggagatgtt gggcaagggg ctccacatgg cccaaaggggca acagatgtctc 1740

```

gcagggcagc tgctgccat gtcacgctc ctgccccct cttcccgct gccacacccc 1800
 accctggcc cccgcagaca cgcatctca actcagtgg gcccagcctt ctggatggct 1860
 tgggttaggc catggggcca cctggggca gggcagcccc tggggcagct ctggaagagc 1920
 agtgtggagg agcaactgtc tgcaagctgg cttcagcctc tggcaactgtc ggagtggtcc 1980
 ctggaggtt ctgcactgtc ggctttggg acgtctcacc cacttgggtt acagttaggcc 2040
 ttccccaccc agagagaagt gttccaccc cagagacatt gtctgtcagc ccctgaagtg 2100
 ctgcctccc ccagtggcc tcaccagccc ttcttatctg tggggccaa gtcaggcttc 2160
 ccctgcggcc accagccata gggagcagcc atcagccccc gagtcagaac tgcttctgtc 2220
 tgtccatacc tccaggctct cccggagagg gggacggata ttatttcct aaagtttgca 2280
 ctaattgtg aggattctca ggattgtgg ggctactga aaagagaat gtgttaatg 2340
 tcgcgttgc tgtccactcg tcctagaagt ttatgtttt tgcactgtc atgtgttct 2400
 gtgggcagag ctgggtctgg agggtggtc agtgcacccg aggctcagag catccatcca 2460
 ccccaactggc cctccttcca gataccctct ctctaattgg gttcttgcattaaaatact 2520
 ccacaataaa taaataattaa aaaaaaaaaaaaaaa 2560

<210> 29
 <211> 614
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1703244CB1

<400> 29
 gtgcaagagg aacaaagaaa gggactcctg cagcgtccgg ctgacctggc cttgtcata 60
 tatctcatcc ttgctggctt cttcaactctg ttccggggcc tgggtggct tgattgcccc 120
 acagatgcct gctttgtcta tatctaccag tatgagccat acctgcggga ccctgtggcc 180
 taccctaagg tgcagatgct gatgtacatg tttatgtcc tgccttctg cggcctggct 240
 gcctatgtc tcacccccc tgggtgtcc tggcttccag actggccctt ggttttgct 300
 ggaggcatcg gccaggca a gttctcgac atgggggctt ccatgcaccc ggcacacccc 360
 ttcacctacc gtgtgcctga ggacacctgg ggctgcttct tcgtgtcata tctgctgtat 420
 ggcgtggcc cccacccctg ggcctaccgt tgccttccgt ggccgcatt ctccaccag 480
 ccaccacccct ccgacccttccac aagaagcagc attgagagag ctgtggactc 540
 aggaccagg actctgttta cgtgcccagt cagccctacc tgggaagcg ggggttgggt 600
 gtttagaga cagg 614

<210> 30
 <211> 1936
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1730819CB1

<400> 30
 gactacgggc tcacagccgt cccttcgtg gtgggaagaa gccgagatgg cggcagccag 60
 cgctggggca acccggtcgc tcctgcctt gctgatggcg gtagcagcgc ccagtgcagc 120
 cggggcagc ggcgtccggg ccgggactgg tgcgcgaggg gctggggcgg aaggtcgaga 180
 gggcgaggcc tggggcacgg tggggctgtc gctggagcac tcatttgaga tcgtatgacag 240
 tgcccaacttc cggaaaggccg gtcactgtc ctggaaaccag caggatgtt ccttgcctt 300
 gtcacacggc cagtcagecg aggaggagcg gggccgactc cgggatgtgg cagccctgaa 360
 tggcctgtac cgggtccggg tcccaaggcg accccggggcc ctggatggcc tggaaagctgg 420
 tggctatgtc tcctcccttg tccctgcgtg ctccctgggt gatgcgcacc tgcggacca 480
 gctgaccctg cacgtggatg tggccgca a cgtgggtggc gtgtcggtgg tgacgcaccc 540
 cgggggctgc cggggccatg aggtggagga cgtggacactg gagctgttca acacctcggt 600
 gcagctgcag ccgcacca cagccccagg ccctgagacg gcccgcctca ttgagcgcc 660
 ggagatggaa caggcccaga aggccaagaa ccccccaggag cagaagtcc tttcgccaa 720
 atactggatg tacatcattc ccgtcgctt gttccctatg atgtcaggag cggcagacac 780
 cggggggccag ggtgggggtg ggggttgg tgggtgggg ggtgtggcc ggtgaggggcc 840
 caggctggc agcgtcccgat ctgcacacc caggggccctc ctttcgtgtt ggagtccct 900
 gtgtccctcg ccattccaa aagggttgc tggcccttcc tttccccccg tcccacgagg 960
 ccacctggc cagcccccttgc tccctgcct tctgctggca gaggagcagc tggactgggg 1020
 ctttgcac agcagccgt gtctcctgc cccgcctccc cdatggccccc atgcagccccc 1080

aggggcttcc cccctgcccc tggagtagag cccgagatcc tggccactat gccagttctg 1140
 acctcgcata cccctacccc gagcccatgc agtctggaa catgccctc tctctccagc 1200
 ctctgtccct ttgttccagg tggtctacc ctccgtccc tggctggct aggtggctc 1260
 gtccaggctc ctgcagcgcc cccctcaact tgacactgga ctaggatgca gcctcccttc 1320
 tgggtccct tgagggtacc ctgggtcccc tcatcagggg cagaggcatg aaagagtccg 1380
 ggctggatgg ccgggggctt ctggggccga cgccctagtgca agccctggg gtcgtggttt 1440
 gacatttgtc tgccctgggtgc aaacaaggaa tccttgccct taaggtaaca gggccctccac 1500
 aggcttccag acttgaaggaa aaaggttaa gaaagaaaaac aaaaccaaca gttagtgag 1560
 tcaaagccca gacactgtaa atagaacccc ctccaccacc ccccgccgccc cagcatccta 1620
 cctggactgc ggtgctacga gggcctgcgg gccttgcgtg tggccaccc tcctgttaag 1680
 tctatttaaa aacatcgacg atacattgaa atgtgtgaac gtttgaaaaa gctacagctt 1740
 ccagcagcca aaagcaactg ttgtttggc aagacggtcc tgatgtacaa gcttgattga 1800
 aattcactgc tcacttgata cgttattcag aaacccaagg aatggctgtc cccatcctca 1860
 tgtggctgtg tggagctcag ctgtgttgta tggcagtttta taaaactgtc ccccagatcg 1920
 acacgcaaaa aaaaaaa 1936

<210> 31
 <211> 1958
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1757161CB1

<400> 31
 gccgcgcctt cagctacggc ccgagcgagc ccggccgcgc cggggccggc cacagcctgc 60
 agcggagccc acgagaggca ggcgcattggc ggagcagacc tactctggg cctattccct 120
 ggtggattcc agtcaagtgt ctacatttct gatttccatt cttcttatag tctatggtag 180
 tttcagggtcc ctaaatatgg accttgaaaaa tcaagataag gagaaagaca gtaatagttc 240
 ttctgggtct ttcaatggca acagcaccaa taatagcata caaacaattg actctaccca 300
 ggctctgttc ctcccaattt gggcatctgt ctcttttta gtaatgttct tccttcttga 360
 ctcaagtccaa gtatgttttta caatatgtac agcagtttctt gcaacgatag ctttgtttt 420
 tcctcttc cccatgtgccc agtatttaac aagaccctgc tcacccatc acaagatttc 480
 ctgggttgc tggcacttgc tcaactgtgc tgatgtgtc tcatttc tgcgtgtcat 540
 gctcgcttc atctgggttc tcactggca ttggcttctc atggatgcac tgccatggg 600
 ccctctgtgc gccatgatcg cctttgtccg cttggccgagc ctcaggatct tcctgcctgc 660
 tcctctcaggg ctctcatact atgatgttctt ttgggtattt tcctcagccat acatcttcaa 720
 tagcaacgtc atggtaagg tggccactca gccggctgac aatcccctt acgttctatc 780
 ccggaagctc cacctggggc ccaatgttgg gctgtatgtt cctcgcttgc tcctgcctgg 840
 aaaactggtc ttcccaagct ccactggcag ccacttctcc atgttggca tcggagacat 900
 cgttatgttgc ggtctctatc tatgttttgc ctttcgtatc gacaactaca aaaagcaagc 960
 cagttggggac tcctgtgggg cccctggacc tggcaacatc tccggcgca tgcagaagg 1020
 ctccctactttt cactgcaccc tcactggata ctttgcgtg ctgctactg ctactgtggc 1080
 gtctcgctt caccggggccg cccagccgc ctttcttat tgggtgcccatttacttttatt 1140
 gcaacttctc acatggcctt atttaaaggcg cttacttgcg cggatgtgtt ctgagccctt 1200
 ccacttcaag tcacggcgtt cccgatttctt ggaagatgttgc tggatcacgt gggaaagtgc 1260
 cagatggccg tcatagttccctt tttctcttcaatgggtt gtttccctt agagctggcc 1320
 tggtaactcag aatgttacccat gtgtttttaagg aacttgcgtg tgactggatt tggcattttaa 1380
 agggagctcg ttgcaggag agaggtgttgc gagccctgtt tggttccctc tccttcgtcg 1440
 gatgttaggg tggggccctt tccaaggaggg acaggccctt ccccaagcgccg ctttcctccc 1500
 acgtttttat ggtatctgcac cagactgttca ctttctgggg gagatggaga ttgtactgtt 1560
 taaaaactga aacacgcgag ggttcttctt acaacttttgg aacactaaaaa ggatgaaaaaa 1620
 aatttagcaaa ccgaagtttcc tcaatgacc cttcgagaac ttgggacca gtttccctatg 1680
 ggggactcag ttccaggagaa ctgagacaga agctttctgtc tggttatatt ctctttccct 1740
 ttttttggat ttatataata ttttctgtgg tggtaacttgc ctttatttccat ccaacagacat 1800
 tgagtgaactt cttaacaacat ccacataaga atttgggttgc atgagttcat gtcacccag 1860
 atgttggttt ggcagtgaac aaggcacgg tttttatatac tacgtacata tatatatata 1920
 aacacacacaca tagatataata tgaataaaca aaaaatgtat 1958

<210> 32
 <211> 1424
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1976095CB1

<400> 32

```

gtcaaggtagg agacaaggag caaagtctta tcacagcggg aggggacgcc agcgccctgca 60
gaggctgagc agggaaaaaaag ccagtcccc acgcggaaagca cagctcagag ctggctcgcc 120
atggacatcc tggtcccact cctgcagctg ctggctcgcc ttcttaccct gcccctgcac 180
ctcatggctc tgctggctg ctggcagccc ctgtgcaaaa gctacttccc ctagctgtat 240
gccgtgctga ctcccaagag caaccgcaag atggagagca agaaacggga gctttcagc 300
cagataaaagg ggcttacagg agcctccggg aaagtggccc tactggagct gggctgcgg 360
accggagcca actttcagtt ctacccacgg gcgtcaggg tcacccctt agacccaaat 420
ccccactttg agaagttcct gacaaagagc atggctgaga acaggcacct ccaatatgag 480
cggttgggg tggttcctgg agaggacatg agacagctgg ctgttgcac catggatgtg 540
gtggctgca ctctgggtc gtgctctgtg cagagccca ggaaggctt gcaaggagg 600
cggagactac tgagacccggg aggtgtcgtc ttttctggg agcatgtggc agaaccatat 660
ggaagctggg ctttcatgtg gcagcaagtt ttcgagccca cctggaaaca cattggggat 720
ggctgctgcc tcaccagaga gaccttggg gatcttgaga acggcccatl ctccgaaatc 780
caaataatggaaac gacagcccccc tcccttggaa tggttacctg ttggggccca catcatggg 840
aaggctgtca aataatctt cccaagctcc aaggactca tttgctccctt cccagcctc 900
caattagaac aagccaccca ccagccatc tatcttccac tgagagggac ctacgagaat 960
gagagaagac attcatgtac caccccttag tccctcttc cccaaacctt gccaggccaa 1020
tctctaactt caatccgc ttcgacagtg aaaaagctt acttctacgc tgaccagg 1080
aggaaacact agacccctgt tttatccca actgcaagtt tctggactag tctcccaacg 1140
tttgcctccc aatgttgc ttttccctcg tttccatggg aaagcttcc tcgctttcc 1200
cctgaggctt caccatgcg tctcttagaa ctggtcacaa aagtcatggt gcctgcattcc 1260
ctgccaagcc cccctggacc tctctccca ctaccatggc tggtggccacc 1320
aggagaatc agagatgtc gggatgccg agcaagactc aaagaggcag aggttttgtt 1380
ctaaatatt tttaataaa tagacgaaac caccaaaaaaaaaaaa 1424

```

<210> 33
 <211> 2238
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 2169991CB1

<400> 33

```

cctgtctgtc cacacccac ggcaagggcc agcctgtttc ctcccggtca cctccaaatc 60
ttgctgttt taattcaact cagaggatag cacttgagggt aggagggcag ggaagtggg 120
gatggcggg catggatggc ccttgaggca ttggctctgg gtgtcatggg ctgtgagat 180
caagaaggcc agtggcctgc ctgacttggg ttggaaaggcc tcacttggc cactgcgg 240
agaactgaaa ctggcaggcc caatttccca ttgttccctgc tttccagggt aggagaat 300
tagattagggtt ctggaggatc aaggtagcag gggctggggg ttgcaggggg atgttgagaa 360
gaagtggcc ttgggtcagg gtgggaagcc aacaggattt cctgggtcat tgaggtgaa 420
agggaaagagg cgctgggtgt tttgttccctgg gcctgagcc ccagaagccg ttggccatcac 480
ctatgacaag ggagacagcc cctggggccag agcccaagtat ggggtgcatt cagggttagat 540
caggaggtat ggtggggccag tgggcagcc aggtggggg ttgtggggg ggcctgggtt 600
gcagggtttaa gcgtgggacc cacgtcagat ttgtggggg tcatgcattgc tgggggtggc 660
ctcagggtctt ccctgttgc tttccactcc caggggctt ctccctccat attccttagc 720
tgggtgggg gcaggacaga gccccttccctt agggaaagccc ggcacccccc gctgtccagg 780
gaagggggatg ctttcttagcc cctgacagat tttttttccccc tcccctggcc tccccaggcc 840
tagccagggtt tggttccca cccacccatgtg ccccccgtcc ttgttacctg gaagcacagc 900
cttggggact gaggccatggcc tcaactgtc ttttccatggc tttaagaagg gaatcggcc ctttggctc 960
accacccctg gggaaagggtt gagaggagag aaggaaagtgg ctgtttggc gctgacaaca 1020
tgaagacttc ctgcgtatgg aacagaggca cagggtccgg ccctgcagcc cccagaacat 1080
ggactggagg gggccatggg gcacccggacc ctggctctgc cctgggtgtt gctgaccc 1140
tgtgtcactg cggggacccc ggaggtgtgg ttcaaggatc ggtggaggc caccgagctc 1200
tcgtccctca ccatccgttgg tgggttccctg gggctggc tcatctccctt ggtgactgtg 1260
agctgggggg gcccccaacgg tgctgggggg accacgctgg ctgttgcac cccagaacgt 1320
ggcatccggc aatggggcccc tgctcgccag gcccgttggg aaaccacagag cagcatctc 1380
ctcatccctgg aaggctctgg ggccagccg ccctgcggcc acaccaccc tctgctgcaag 1440
tttgcgttcc tccctggggg ctcctgggg gctgtggg gcttccggcc cagctcagac 1500
ccagggtctt ctggccggcc gactcctgc cccattctgc gggcagaccc gcccgggatc 1560

```

ttgggggtct caggagtctt cctcttggc tgggtctacc tccttcatct gctgcgccga 1620
 cataaggacc gcacctgcccc taggctccag ccgtcccgca ccagcccca ggacccgaga 1680
 gcacgagcat gggcaccaag ccaggccctcc caggctgctc ttacacgtccc ttatgccact 1740
 atcaacacca gctgcccggc agctactttg gacacagctc acccccatgg gggccgtcc 1800
 tggtggcggt cactccac ccacgctgca caccggccccc agggccctgc cgccctggcc 1860
 tccacaccca tcctgcacg tggcagctt gtctctgtt agaatggact ctacgcttag 1920
 gcaggggaga ggcttcctca cactggtccc ggctcaactc tttccctgaa ccctcgaaaa 1980
 cccaggccca tggaaaggacc cttaggagtt cgatgagaga gaccatgagg ccactggct 2040
 ttcccttc caggcctcct ggggtctacc cccttacttt aattcttggg ccctccaataa 2100
 gtgtccata ggtgtctggc caggccacc tgctgcggat gtgggtcttg tgggtgcgtg 2160
 tgtggccaca ggtgtgagtg tggagtgac attacccca ttccatgtcat ttccctgctgc 2220
 aactaagtca gcaacgcc 2238

<210> 34
<211> 536
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2616827CB1

<400> 34
 gcatgaactt gggggtcagg atgctgagga tcctcttcct cctggatgtt ggaggagctc 60
 aagtgcgtgc aacaggcaag acccctgggg ctgaaaattgtt ttcaagtac gcccctatcg 120
 ggactgtgtt ggggtcgcc atatctgtt gcttcctggc cctgaagatc tgcatgatca 180
 ggaggcaactt attgacgac gactctccg acctgaaaag cacgcctggg ggccctcagt 240
 acaccatccc gctaaagaag agagcccaa ggcgaaacca caatttcctcc aaaagagatg 300
 cacaggtgat tggatgttag gtgagcagtg acgtgaagag gggttcttagc cccgtggaaa 360
 acagcccatg gtaacatct caggatgtt tgcatattttt caccctaaaggc tggtaatgaa 420
 ctttcacatg gactgaatat tggaggcaaa taatagaagg aatagaatat acagtgcctc 480
 tgtccctgaa gaaaatatca tgcctttctt ggaagaaacg gactgcacag aggaag 536

<210> 35
<211> 2177
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2991370CB1

<400> 35
 cgggaggctc gaggccagcc cgggaccggg gctgggagca agcaggccggc ggcgcggcg 60
 gcagaggccgg cagcgagcgc ccgccttccca cggcccttagg cggcggggcc gagagcggga 120
 ggatggctcc gagcgttgcac cccggcatgt ccaggatgtt accgttccctg ctgctgtct 180
 ggttctgccc catcaactgag gggtcccgac ggctgaacc catgttcaact gcaacttacca 240
 actcaggatct tccttcgtac tatgacagta atccccccca gctcaactat ggtgtggcag 300
 ttactgtatgtt ggaccatgtat gggactttt agatcgtcgtt ggcggggtagt aatggaccca 360
 acctgggtctt gaagtatgac cgggcccaga agcggcttgtt gaacatcgat gtcgtatgagc 420
 gcagctcacc ctactacgcgc ctgcgggacc ggacggggaa cggccatggg gtcacagcc 480
 ggcacatcga cggggacggc cgggaggaga tctacttcctt caacaccaat aatgccttct 540
 cgggggtggc cactgtacacc gacaaggatgtt tcaagttccg caataccgg tggaaagaca 600
 tcctgagcga tgaggtaac cggccctgtt gtggggccat ccttcctgaa ggacgctctg 660
 tggcctgtgtt ggacagaaaag ggctctggac gctactctat tcatatggcc aattacgcct 720
 acggtaatgtt gggccctgtat gcccctatgg aatggaccc tgaggccat gacctctccc 780
 ggggcattctt ggcgttcaga gatgtggctg ctgaggctgg ggtcagcaaa tatacagggg 840
 gcccggcgtt cagcgtggcc cccatctca gcaacgtgc ctcggatatac ttctgcgaca 900
 atgagaatgg gcctaacttc cttttccaca accggggcga tggcacctt gtggacgctg 960
 cggccagtgc tgggtgtggac gaccccccacc agcatggggc aggtgtcgcc ctggctgact 1020
 tcaaccgtga tggcaaaatgtt gacatgttctt atggcaactg gaatggccccc caccgcctct 1080
 atctgcaat gacccat gggaaaggatcc gcttcggggat ctcgcctca cccaaatgttct 1140
 ccatgccttc cccatgtccgc acggcgtatca cccggactt tgacaatgac caggagctgg 1200
 agatcttctt caacaacattt gcttcctcggc gtcctcgttca accccgcctc ttccgcgtca 1260
 tccgttagaga gcaacggagac cccctcatcg aggagctcaa tcccgccgac gccttggagc 1320

ctgaggggccg	ggcacaggg	ggtgtggtga	ccgacttcga	cggagacggg	atgctggacc	1380
tcatcttgc	ccatggagag	tccatggctc	agccgctgtc	cgtttccgg	ggcaatcagg	1440
gcttcaacaa	caactggctg	cgagtggtgc	cacgcacccg	gtttggggcc	tttgcaggg	1500
gagctaagg	cgtgtctac	accaagaaga	gtggggccca	cctgaggatc	atcgacgggg	1560
gctcaggcta	cctgtgtgag	atggagcccg	tggcacactt	tggcctgggg	aaggatgaag	1620
ccagcagtgt	ggaggtgacg	tggccagatg	gcaagatgtt	gagccggaac	gtgccagcg	1680
gggagatgaa	.ctcaagtgt	gagatccct	acccccggga	tgaggacaca	cttcaggacc	1740
cagccccact	ggagtgtggc	caaggattct	cccagcagga	aatggccat	tgcattggaca	1800
ccaatgatg	cattcaggat	ccatctgggt	gcccctcgaga	caagccctga	tgttcaaca	1860
cctatggaaag	ctacagggtgc	cggaccaaca	agaagtgcag	tcgggggtac	gagcccaacg	1920
aggatggcac	agcctgcgtg	ggctgggtga	gcccctgtgtt	gaagatagt	acaccacaa	1980
ttggaaagag	ccttggtccc	tgaatcaact	aatcaactgcc	ttgaatcacc	gccttggata	2040
cctgttgatc	aggaacactt	accttggaaact	tcacttgagca	ggataaaaaac	tttatattgt	2100
ttaagctatt	aatacattaa	gatttggggg	tgctacccctt	cataataaaat	tcccatattcc	2160
tcttgaaaaa	aaaaaaaa					2177

<210> 36
<211> 2043
<212> DNA
<213> Homo· sapien

<220>
<221> misc_feature
<223> Incyte ID No: 3031062CB1

<210> 37
<211> 1743
<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3101617CB1

<400> 37

cagcagggtca	cagccccctcg	aggcgacagc	ggcccccgcg	caccagagca	gtgggtacagg	60
catggatggg	aagaatgcg	gcgttatggat	tttcttacact	tttgtatcca	ctttgtttac	120
ttcagctgg	tttggttag	tataacttcat	agctgtggaa	gatgacaaaa	tttaccatt	180
aaattcaact	gaaaggaaac	ctgggtgtgaa	gcatgcacca	tatataagca	ttgcagggt	240
tgatccct	gcaagctgt	tgtttagtca	agtatgaac	atggcagcct	tcctagccct	300
tgtgttagct	gttctgcgt	tcatacacaact	gaaaccgaag	gttttaaac	cgtggctgaa	360
tattagtgga	ttggggctc	tgtgtctggc	ttcccttcggg	atgacccctac	ttggtaattt	420
tcagctcaca	aatgtgaag	aaatccataa	cgtggaaact	tccttgacct	ttggatttgg	480
cacattgacc	tgctggatcc	aggctgcgt	gacactcaag	gtcaacatca	agaatgaagg	540
acggagagtt	ggaattccac	gggttattct	gtcgccatct	atcacttct	gtgtggctc	600
ctacttcate	ctcatggccc	aaagcatcca	catgtatgca	gccagggtcc	atgggggcct	660
ggtcatgtc	ttcctgtctt	atttggcac	cttgcctgt	gagttccggc	attaccgcta	720
tgagattgtt	tgctctgagt	accaggagaa	tttcctaagc	ttctcagaaa	gcctgtcaga	780
agcttctgaa	tatcagactg	accagggtgt	aaccatcagt	ttttccttgc	ttggtaggg	840
ggtgtgacac	tggggggaggg	gccagtagga	cacactcaca	ggacttgcaca	tagaacctca	900
tttcacacac	acacacacac	acacattcat	ggccacattt	gccaaattgag	cttttcaggg	960
cgagttattt	cttaatgaa	aaagcacaag	cccttatgt	tgc当地taca	cgctgttaca	1020
ctggaaaat	atgcacgac	gagaagaag	cttgcacat	atacttctt	atccgtcccc	1080
ttcccagcac	tccctccct	tcccatttctc	tccacatgtc	tcaagcaccc	taccgagtag	1140
ggcaggccaa	atttccctt	ggagtaatgc	caactcccg	cgttgccttc	aggcacaag	1200
ggcttggaaac	cagctcgta	ggaagttctg	aatctggcac	taatatttctt	gagtggataa	1260
tagtgtatca	tagaattagga	cggaaattgt	atttagatgt	gaccctgtgt	cgccctgtgga	1320
aaggcatagt	gagaagaact	ttcccacgaa	agcccccttc	atcggttgc	agtggctggc	1380
tgtgtggatc	ccaggagaga	catatgccac	agactgtgag	agcaaaagccc	gccgctgtga	1440
tctggacttg	atgcaactgt	actgagaatg	atttccaaat	gtgaatatgt	gtaggacgt	1500
ggtctatcg	gccttggaaaca	agatgggggc	agtgaaggt	ttgttttagt	tttgcttca	1560
tagatgcca	tgtacaatgt	tttatatttc	atagtttctt	ttaagtaact	accatgagtc	1620
tctctaagcc	tcatggacaa	agatgtagac	caaatacgaa	agctgagctt	gctttgggtt	1680
caaccatgtat	caaagaaaaaa	ctgagggtc	ctgcaggctt	acgtggaaag	ctaagacaat	1740
atc						1743

<210> 38

<211> 1306

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3216178CB1

<400> 38

ctgcaaagt	cctgtgagcg	ctgtcattt	gtcaactctgg	tttttcagat	tcttccccctg	60
gaggcgtggag	tttccaggat	gtcaaaatta	cctctgcttgc	ggtgagctat	ttcaaggcagc	120
tgggataacct	gtgtcaactcc	tgctgtctgc	cagtgaactgc	ccagggtgtct	gctggttcct	180
ccccaggagt	agggaggaac	caggtggct	ggctgggatg	ggtgatatt	taaagaccag	240
gccttgacg	ctgcagca	tctatctctg	cttgatgcct	gtgcacagt	ggctggtect	300
cctccctctg	ctgtggctga	gccttgggt	gaagacaggc	agtcgtccc	aacccaggaa	360
ccttgcgt	cttgggacgg	atcaccactg	caagaggggc	atgtgcatt	gtgtatgaaatt	420
ctgcatgtg	gcaccagact	gccaccaga	ccacagtgtc	ctctgcaacc	ctgcttctca	480
gatgaccaag	atggtgctgc	agatgggtct	gaggatggag	aacccaccaa	gccccgctag	540
gagccaccta	gactggatgc	agagcatgg	gagctccctg	caggttctct	gagaagggg	600
ggatggcagc	ctgctccttg	ccttttgcc	ctccaggccc	caaagtccagg	gaaccaaag	660
aagaaaagggg	ccttagctag	ggcagagctc	cactgcaatg	attgttttag	ggtagggagc	720
caggatgtcc	gtctgtggac	actgaaattt	gaatctcata	tacttttgt	acaaaacatt	780
cttcccttt	tgttcttc	cttaccatcta	aaaatgtaga	aaacatctt	agcttatgag	840
ttgcacaaaa	acaggcgt	gccagatttgc	gccatagac	catagtttgc	tgacttctgc	900
cctaaatcat	cctccatttc	tttccttctg	tgtccttgc	actgacaaag	ccacttccc	960
taaaaatgggg	tctttccctg	tttggtgcc	tgaagccaat	atgacaaaacc	gaaagtggagc	1020
ctcaaggcgt	gcaggctta	tttggtgcc	atggaattga	gaagtggag	cttggctcac	1080

```

aaatcaacctt ttctgctcggt gagaccggagg aagtccacaga tacagggcat ctttagtgaa 1140
ggggctgagc attaaaagca agggggaggag tggccaggtg caatggctca ctccccataaaa 1200
cccagaacctt tggggaggcca aaatgagagg attgctgaga ccagggatgtc gagaccatcc 1260
tgttcaacat agtgatacac ccccatctct aaaaaataaa aatga 1306

```

<210> 39
<211> 851
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No: 3406803CB1

```

<400> 39
gggctggcca cactgcaggc gctgcagggaa gcaaaggatg aaactgatct tttcaactaac 60
cagcataggg cacaggccaa agaaaacctt ggtaactctc ttgtgagccca gttgaagtt 120
gacttgttct ctttggaaata ggtcttcctc tgcaaaaaata aaaacacttg tctgaaagag 180
gctgtacta tctgtgggct gttgggcaag gacacttcag atactggctt tgagctca 240
gggtccctggc ccctcatggc tctgtatca tctctgtctc acattgcagg ccatgctccc 300
tgggtgtct cagccccagga gcccctctt ggtcctggcc agactccccc accctctgtgg 360
gcctgcccaca accagtcttag tgcctttct cccatggggg tccctggaaat ctacacacacc 420
ctggcccttac agagcctgca gtccagggtg ggagtttaacc ctttccactt tcccgagag 480
ggagacccctt agtggagggg aggtcaggaa acgcggggct ggcagcatgg tggaggagg 540
tggaaagtacg atgaccagag ccttgtgtgt gcgcgtgtt acaaagctga gggtatgtat 600
gggtgcgtgt gcaggcgctg cctgagaaga ccactcctga tggagtgtt ggggaagttc 660
aaggcttggg ggcacatgg agggctgtatgt gcacccatcc agtggagagg ctgtattttgg 720
aggcccttctt gagttgggatc aaggctatgt ggatgtatgg atggatgtt aagatggaa 780
gtggctgtac gaacagccat tgaggctgtatgt gcaggaggat tgcctaagtc catagccccag 840
gtgtcgagac t 851

```

<210> 40
<211> 2204
<212> DNA
<213> *Homo sapiens*

<220>
<221> misc_feature
<223> Incyte ID No: 3468066CB1

<400>	40					
gaggcagtcc	tgtggtccc	cccccgctc	ggctcgccg	caggggacgc	tagtgggtcc	60
agtctcctt	gcaaccactt	gtcctccccc	ctccggccct	ttaacctta	ggtgcgccgg	120
gtgcagata	tctcgcgctc	tctcccttt	cccccccccc	ttttccacc	ccgggcgcctc	180
aggtgtgtct	ggaccggaag	cgaagatggc	gacttctggc	gcggcctcg	cggagctgg	240
gatcggctgg	tgcattattcg	gcctcttact	actggctatt	ttggcattct	gctggatata	300
tgttcgtaaa	taccaaagt	ggcgggaaag	tgaagttgtc	tccaccataa	cagcaatttt	360
ttctcttagca	attgcactt	tcacatcagc	acttctacc	gtggatata	ttttggttc	420
ttatcataaaa	aatcaaatt	gtacattaa	ggactggct	aatgctaatt	ttagcagaca	480
gattgaggac	actgttattat	acggttacta	tactttat	tctgttat	tgttctgtgt	540
gttctctgg	atccctttt	tctacttcta	ttatgaagaa	aaggatgt	atgatactag	600
taaatgtact	caaattaaaa	cggcactcaa	gtatacttt	ggatttgg	tgatttgtgc	660
actgcttctt	ttagttggt	ccttggtcc	attgaatgtt	cccaataaca	aaaattctac	720
agagtggaa	aaagtgaagt	ccctattga	agaacttgg	agtagtcat	gttagctgc	780
attgtcattt	tctatcagtt	ctctgacctt	gattggaat	ttggcagct	taacttacac	840
agcctatggc	atgtctgcgt	tacctttaaa	tctgataaaaa	ggcactagaa	gcgctgccta	900
tgaacgttt	gaaaacact	aagacattga	agaagtagaa	caacacattc	aaacgattaa	960
atcaaaaagc	aaagatggc	gaccttgc	agcaaggat	aaacgcgcct	taaaaacaatt	1020
tgaagaaaagg	ttacgaacac	ttaagaagag	agagaggcat	ttagaattca	ttgaaaacag	1080
ctggtgtggaca	aaattttgt	gcgctctgc	tccctgt	atcgctgg	gaatattttt	1140
catcttagtt	gcattgtgt	ttgttaattt	tcttttctt	tcaatttag	ataaagctct	1200
tcttcgtact	ggaatagat	ctggtttcat	aatttttgg	gctaactga	gtaatccact	1260
gaatatgtctt	ttgccttac	tacaaacagt	tttccctt	gattat	ttataacaat	1320
tattattatg	tactttattt	ttacttca	ggcaggaaatt	cgaaatatt	gcatatgg	1380
cttttgatt	agattatata	aaatcagaag	aggtagaacc	aggccccaa	cactccttt	1440

tctctgcatg atacttctgc ttattgtcct tcacactagc tacatgattt atagtcttc 1500
 tccccaatat gttatgtatg gaagccaaaa ttacttaata gagactaata taacttctga 1560
 taatcataaa ggcaattcaa cccttctgt gccaaagaga tgtatgcag aagctcctga 1620
 agatcagtgt actgttaccc ggacataacct attccctcac aagttctggt tcttcagtgc 1680
 tgcttactat tttgttaact gggccttct tgggttattt ttgattggat taattgtatc 1740
 ctgttgtaaa gggaaagaaat cggttattga aggtagat gaagatttag acataagtga 1800
 tcatgagccc tctgtctatt ctgttgcaca gccttctgtc ttaaagggtt tataatgtcg 1860
 actgaatatac ttttatgtat ttttaaagta ttaaactaac attaggattt gctaactagc 1920
 tttcatcaaa aatgggagca tggctataag acaactataat tttattataat gtttctgaa 1980
 gtaacattgt atcatagatt aacatttaa attaccataa tcatgctatg taaatataaag 2040
 actactggct ttgtgagggaa atgtttgtc aaaattttt cctctaattgt ataatagtgt 2100
 taaattgatt aaaaatctc cagaattaat attccctttt gtcactttt gaaaacataa 2160
 taaatcatct gtatctgtgc cttaggttct caaaaaaaaaaa aaaa 2204

<210> 41
<211> 570
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3592862CB1

<400> 41
gccccggggc tcggggagtc ggcgcctatga ccccatcgag gcttccctgg ttgcttagct 60
gggtctccgc cacggcggtgg agagcgc当地 gatcaccctt tctgtgtcat tctctgagga 120
aaacaagttc ttctcaagga ggaaaagtctg aacttgc当地 acagtcctt aagaagccga 180
agttaccaga aggtcggttt gatgcaccag aggattccca ttttagagaaa gaaccactgg 240
aaaaatttcc agatgatgtt aatccagtgaa ccaaagaaaa aggtggaccc aggggcccag 300
aacctacccg atatggagat tgggaacgaa aaggacgctg tattgatttt taagtgc当地 360
attcttaac ttcaatattt ttttctgat atgtacatct gaattaactt atttctgatt 420
attttcttcc ttatatatcct ttatgtcggtg tagtttgtt aatgtgttta aatataata 480
tatatatata tatatatata tatatatatg ggggcttagg aagaaaatat gctgctgtaa 540
attagggaaag ggagaccagc ctgaccaata 570

<210> 42
<211> 802
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3669422CB1

<400> 42
caggggtcaag gtgaagctgg tgggtctcg aggccgggtga gtgtcatggg ggagcctggg 60
tgggggtcac actggctctc tctagtccca tgcgtcgct ctcttcacga tgccctctccc 120
cttccccagg gatgtctctg tggagctgcc ttttgc当地 atgcacccca agcccccacga 180
ccacatcccc ctccccagac cccagtcagg tgacccact acccaccacca agccctcaga 240
gggagggcct gaagcaggccc cagtggagga aaactggccc ttccagcacc caccggccaca 300
cccccttc当地 ccgtcccccc agccccc当地 ccctccctt cactggaaag ctcttc当地 360
caatcccttc acactctctc cccatcccc ccaagataca cactggaccc tctctgtctg 420
aatgtggca ttaattttt gactgc当地 ctgttctcc agcccccccg tgggtggcaa 480
gctgtgttca tacctaaatt ttctggaaagg ggacagtga aagaggatg acaggaggaa 540
aagggggaga caaaaactcct actctcaacc tcacaccaac acctccctt atcactctct 600
ctgccccat tccttcaaga ggagaccctt tggggacaag gccc当地 tttt tttt 660
aaaaaggtta gaagggcccc cctctctgaa ggccccccact ccctggatg ctacaatcca 720
atgatgaaag atggcattag ctacaccacc ctgc当地 ttttcc ccgagatgaa cataccacga 780
actggagatg cagagtctc ag 802

<210> 43
<211> 693
<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3688740CB1

<400> 43

gttggtttaa tgggattgtg gaagagaatg actccaatat ttggaagtgc tggcacacca 60
 atcaggcacc gtccaaagaac tgcacacatg cttacctgtc tccgtacccc ttcatgagag 120
 gcgagcacaa ctgcacccctc tatgactctg cagttatcta ccgtgggttc tgggcagtcc 180
 ttagtgcctt ggggttagtt gctgttagtca tcgcaagctt tttgatcatc tggcagcccc 240
 ctttcggccag ccattttctc tacaaagctg gggggaggctc atatattgtc gcagatggaa 300
 tttttctctt ctgttactca agcctctcaa agtcccttatt gtcccagcct ctgcgtgaaa 360
 cgtttcagc catcaatgac atctcactcc ttcaagccct tatgccactg ctgggatggaa 420
 ccagtcaactg gacctgcatt acagtggct tatattgacc tttacctcta cacttgtata 480
 taactcgttt tcccatattag ttgcaagaca cttggaaagca cagaccaagg cttacatttg 540
 tgtttaatg ttttcttgc aaatgcctta tgccataatg tttctgtact actcttctt 600
 ccaaatctt attgtttaaa agtttctctc ctactatacc atgccttata aatattgatt 660
 gaatgaatgg atgaaatgca tacctgttta tag 693

<210> 44

<211> 1212

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3742589CB1

<400> 44

ccctcgaggc aacttgcct tctcaaacat gcccggccacg gcccctctgg aagggAACCG 60
 ctctgggccc cgcccttgat ctgcgttggc gggctggggg atgagagctg caccgcgcgg 120
 gacaagtgcg cggcgccgcg ccacggagca gaacagagag catggagctg gagaggatcg 180
 tcagtgccgc cctcccttgc ttgtccaga cacacctccc ggaggccgac ctcagtggct 240
 tggatgaggt catcttctcc tatgtgttgc gggctctggc ggacctggc ccctcggggcc 300
 catcagagga gaacttcgtat atggaggttgc tcaactgatgat gatggaggcc tatgtgcctg 360
 gcttcggcca catccccagg ggcacaatag gggacatgtat gcagaagctc tcagggcagc 420
 tgagcgatgc caggaaacaaa gagaacctgc aaccgcagag ctctgggtc caaggtcagg 480
 tgcccatctc cccagagccc ctgcagccgc ccgaaatgtt caaagaagag actaggctt 540
 cggctgtgc tgctgcagac acccaagatg aggcaactgg cgctgaggag gagcttctgc 600
 caggggttgc tgacttctgc gaggtgttcc ctacctgttgc ggtggagcag gcccagtggg 660
 tgctggccaa agtcgggggg gacttggaaag aagctgtc gatgtggta gaggaaagg 720
 aagagggggcc tgcagcctgg gaggggccca accaggaccc gcccagacgc ctcagaggcc 780
 cccaaaagga tgagctgaag tccttcatcc tgcaagaatgtt catgtgggt gatagcgcag 840
 aggtatcagaa gattcaccgg cccatgttc ccaaggaggc ccccaagaag ctgatccgt 900
 acatcgacaa ccaggtagtgc agcaccaaag gggagcgatt caaatgttgc cgaaaccctg 960
 agggccgagga gatgaaggcc acatacatca acctcaagcc agccagaaag taccgcgttcc 1020
 attgaggcac tcgcccggact ctgcggcgttcttgc cttcttaggtt cagatcccg aggatgcag 1080
 gagccctata cccctacaca gggggccccc aacttctgtc ccccttcttcttactcacttgc 1140
 tccatagtgtt aacctactc tcggagctgc ctccatggc acagtaaagg tggcccaagg 1200
 aaaaaaaaaaa aa 1212

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number
WO 00/52151 A3

- (51) International Patent Classification⁷: C12N 15/00,
C07K 14/47, G01N 33/53
- (21) International Application Number: PCT/US00/05621
- (22) International Filing Date: 3 March 2000 (03.03.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/123,117 5 March 1999 (05.03.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/123,117 (CIP)
Filed on 5 March 1999 (05.03.1999)
- (71) Applicant (*for all designated States except US*): INCYTE PHARMACEUTICALS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). LU, Dyoung, Aina, M.
- [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US).
- (74) Agents: HAMLET-COX, Diana et al.; Incyte Pharmaceuticals, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *With international search report.*

(88) Date of publication of the international search report:
26 April 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A3

WO 00/52151 A3

(54) Title: HUMAN SECRETORY PROTEINS

(57) Abstract: The invention provides human secretory proteins (HSECP) and polynucleotides which identify and encode HSECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSECP.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/05621

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/00 C07K14/47 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 99 22243 A (ENDRESS GREGORY A ;FLORENCE KIMBERLY A (US); HUMAN GENOME SCIENCES) 6 May 1999 (1999-05-06) abstract page 101 -page 102 Seq.Id.No.215 ---	1-23
A	SHIROZU M ET AL: "CHARACTERIZATION OF NOVEL SECRETED AND MEMBRANE PROTEINS ISOLATED BY THE SIGNAL SEQUENCE TRAP METHOD" GENOMICS, US, ACADEMIC PRESS, SAN DIEGO, vol. 37, no. 3, 1 November 1996 (1996-11-01), pages 273-280, XP002054773 ISSN: 0888-7543 the whole document ---	1-23 -/-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 September 2000

Date of mailing of the international search report

05.1.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/05621

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JACOBS K A ET AL: "A genetic selection for isolating cDNAs encoding secreted proteins" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, GB, ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 198, no. 1-2, 1 October 1997 (1997-10-01), pages 289-296, XP004116069 ISSN: 0378-1119 the whole document ---	1-23
A	WO 98 30696 A (GENETICS INST) 16 July 1998 (1998-07-16) the whole document ---	1-23
A	WO 98 32853 A (GENETICS INST) 30 July 1998 (1998-07-30) abstract ---	1-23
A	WO 98 40486 A (GENETICS INST) 17 September 1998 (1998-09-17) abstract -----	1-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/05621

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 16, 19 and 22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-23 (PARTIALLY)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-23 (partially)

An isolated polypeptide having sequence as set forth in Seq.Id.No.1 of the sequence listing and its nucleic acid sequence as set forth in Seq.Id.No.23. Methods of production and uses thereof.

2. Claims: 1-23 (partially)

Inventions 2-22:

Same as for invention no.1 but respectively to each following pair of aminoacid sequences with their respective nucleic acid sequences:

Invention 2: Seq.Id.Nos.2 and 24.

Invention 3: Seq.Id.Nos.3 and 25.

....

Invention 22: Seq.Id Nos.22 and 44.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/05621

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9922243 A	06-05-1999		AU 1273499 A EP 1042674 A AU 1118499 A WO 9921575 A	17-05-1999 11-10-2000 17-05-1999 06-05-1999
WO 9830696 A	16-07-1998		US 5945302 A US 5972652 A AU 2723397 A EP 0907732 A EP 1007660 A JP 20000508172 T AU 5822398 A AU 2558599 A EP 1047713 A WO 9935168 A	31-08-1999 26-10-1999 29-10-1997 14-04-1999 14-06-2000 04-07-2000 03-08-1998 26-07-1999 02-11-2000 15-07-1999
WO 9832853 A	30-07-1998		AU 5828398 A EP 1007661 A	18-08-1998 14-06-2000
WO 9840486 A	17-09-1998		US 5976837 A AU 6702298 A EP 0973890 A	02-11-1999 29-09-1998 26-01-2000